

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 1/00, C12N 15/67	A1	(11) International Publication Number: WO 98/10089 (43) International Publication Date: 12 March 1998 (12.03.98)
(21) International Application Number: PCT/DK97/00373 (22) International Filing Date: 8 September 1997 (08.09.97) (30) Priority Data: 0963/96 6 September 1996 (06.09.96) DK (71)(72) Applicant and Inventor: JENSEN, Peter, Ruhdal [DK/DK]; Søgårdsvej 19, DK-2820 Gentofte (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): SNOEP, Jacky, Leendert [NL/NL]; Joubert Straat 5 A, NL-1091 XM Amsterdam (NL). WESTERHOFF, Hans, Victor [NL/NL]; Charlie Parker Straat 25, NL-1066 CX Amsterdam (NL). (74) Agent: HOFMAN-BANG & BOUTARD, LEHMANN & REE A/S; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A METHOD OF IMPROVING THE PRODUCTION OF BIOMASS OR A DESIRED PRODUCT FROM A CELL		
(57) Abstract <p>The production of biomass or a desired product from a cell can be improved by inducing conversion of ATP to ADP without primary effects on other cellular metabolites or functions which is achieved by expressing an uncoupled ATPase activity in said cell and incubating the cell with a suitable substrate to produce said biomass or product. This is conveniently done by expressing in said cell the soluble part (F₁) of the membrane bound (F₀F₁ type) H⁺-ATPase or a portion of F₁ exhibiting ATPase activity. The organism from which the F₁ ATPase or portions thereof is derived, or in which the F₁ ATPase or portions thereof is expressed, may be selected from prokaryotes and eukaryotes. In particular the DNA encoding F₁ or a portion thereof may be derived from bacteria and eukaryotic microorganisms such as yeasts, other fungi and cell lines of higher organisms and be selected from the group consisting of the gene encoding the F₁ subunit β or a portion thereof and various combinations of said gene or portion with the genes encoding the other F₁ subunits or portions thereof. The method can be used i.a. for optimizing the formation of biomass or a desired product by a cell by expressing different levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate is optimized.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A method of improving the production of biomass or a desired product from a cell

This invention relates to a method of improving the production of biomass or a desired product from a cell by inducing conversion of ATP to ADP without primary effects on other cellular metabolites or functions. The invention also relates to a method of optimizing the production of biomass or a desired product from a cell utilizing this first method. The desired product may for example be lactic acid produced by lactic acid bacteria and ethanol or carbondioxide produced by yeast.

BACKGROUND OF THE INVENTION

A wide range of microorganisms are used for the production of various organic compounds and heterologous proteins. One example hereof is the production of lactic acid and other organic compounds by the lactic acid group of bacteria, which results in the acidification and flavouring of dairy products, better known as cheese and yougurt production.

From the microorganism's point of view, the organic compounds which are excreted from the cells are often merely the by-product of a process that is vital to the cells: the production of various forms of free energy (ATP, NAD(P)H, membrane potential, etc.). Therefore, although many of the microorganisms which are being employed in these processes are reasonably well suited for the purpose, there is still a great potential for optimizing the productivity of these organisms when looking from the bioreactor point of vue. Likewise, the production of heterologous proteins by a microorganism is not what the organism was adapted for and also here there is a potential for optimization.

Often when microorganisms are engineered for the purpose of optimizing an industrial production process, the reactions leading to the desired product will affect the delicate balance of co-factors involved in the energy metabolism of the cell. For instance if the glycolytic reactions producing lactate from sugar were somehow to be enhanced (e.g. by overexpressing the glycolytic enzymes) this would automatically lead to the conversion of ADP to ATP. The ratio between the concentrations of ATP and ADP is usually quite high in the growing cell ($[ATP]/[ADP] > 10$), and when the ratio $[ATP]/[ADP]$ changes, the sum of $[ATP]$ and $[ADP]$ still remains virtually constant. Therefore, if in the example above, the enhanced production of ATP changes the $[ATP]/[ADP]$ ratio from 10 to say 30, this will only marginally affect the concentration of ATP. The ADP concentration however will change by a factor of three. The cells will then hardly feel the surplus of ATP but the ADP pool in the cells may be depleted to such an extent that reactions in which ADP is a co-factor or allosteric regulator will be suppressed by the lack of ADP. The result may be that the total flux through the pathway (here through glycolysis) is only marginally increased. In the future, this situation is likely to occur more frequently, as the productivity of bioreactors are optimized by other means, and in these cases, it will be even more important (compared to the normal cell) to regenerate the ADP from ATP, in order to further increase the productivity.

Previously, attempts have been made to decrease the intracellular ATP concentration in yeast, employing sets of reactions which together form futile cycles, see EP patent No. 245 481. Often, the first reaction of a futile cycle is part of the regular metabolic network of the cell, for instance the phosphorylation of a glycolytic intermediate, coupled to the utilisation of ATP. The second reaction, which may also sometimes be part of the

metabolic network, then de-phosphorylates the glycolytic intermediate without regenerating the ATP that was consumed in the first process, the overall effect being that a high energy phosphate bond is consumed. The limited
5 success that this strategy has had so far, is probably due to the fact that it is impossible to obtain a significant futile flux without decreasing the concentration of the phosphorylated intermediate, thereby disturbing the cellular function and ultimately the growth. In addition,
10 tion, when the approach is to decrease the concentration of a glycolytic intermediate, this will effectively remove the substrate for the remaining part of the glycolysis, which will often result in a decreased flux through this pathway, rather than the desired increased flux.

15 Other strategies have been to use chemicals such as dinitrophosphate to stimulate the activity of the plasma membrane H^+ -ATPase by the addition of uncouplers of the membrane potential, or to genetically express the enzyme
20 acid phosphatase in the cytoplasm, an enzyme that will remove phosphate groups from organic metabolites and proteins. However, both of these approaches suffer from the same inherent problem: they are unspecific and a range of cellular reactions/concentrations may be affected. For
25 instance, the acid phosphatase will remove phosphate groups from essential metabolites and proteins, thus disturbing various metabolic fluxes and metabolic regulation. The uncoupling of the plasma membrane H^+ -ATPase will disturb the intracellular pH in addition to the gradient of numerous ions across the cytoplasmic membrane.
30 Besides, the addition of chemicals such as dinitrophosphate is undesirable for most purposes.

SUMMARY OF THE INVENTION

35

The idea of the invention is to use a highly specific and clean way to increase the intracellular level of ADP,

WO 98/10089
4
which does not suffer from the limitations described above: to express in a well-controlled manner an enzyme that has ATP-hydrolytic activity in the living cell without producing other products and without coupling this activity to energy conservation. Such an enzymatic activity is of course not likely to be found in a normal cell, because the cell would then lose some of its vital energy reservoir.

10 Accordingly the present invention provides a method of improving the production of biomass or a desired product from a cell, the method being characterized by expressing an uncoupled ATPase activity in said cell to induce conversion of ATP to ADP without primary effects on other
15 cellular metabolites or functions, and incubating the cell with a suitable substrate to produce said biomass or product.

One of the normal enzymes that comes closest to the
20 ideal ATP-hydrolyzing enzyme, is the membrane bound H^+ -ATPase. This huge enzyme complex consists of two parts, the membrane integral part (F_0) and the cytoplasmic part (F_1). Together the two parts couples the hydrolysis of ATP to ADP and inorganic phosphate (P_i), to translocation
25 of protons across the cytoplasmic membrane, or vice versa, using the proton gradient to drive ATP synthesis from ADP and P_i .

The method of the invention is conveniently carried out
30 by expressing in said cell the soluble part (F_1) of the membrane bound (F_0F_1 type) H^+ -ATPase or a portion of the F_1 exhibiting ATPase activity.

The membrane bound H^+ -ATPase complex is found in similar
35 form in prokaryotic as well as eukaryotic organisms, and thus F_1 and portions thereof expressing ATPase activity

can be expressed in both prokaryotic and eukaryotic cells.

The organism from which the F₁ ATPase or portions thereof is derived, or in which the F₁ ATPase or portions thereof is expressed, may be selected from prokaryotes and eukaryotes, in particular from bacteria and eukaryotic microorganisms such as yeasts, other fungi and cell lines of higher organisms, in particular bakers and brewers yeast.

A particularly interesting group of prokaryotes to which the method according to the invention can be implemented, i.a. in the dairy industry, are lactic acid bacteria of the genera *Lactococcus*, *Streptococcus*, *Enterococcus*, *Lactobacillus* and *Leuconostoc*, in particular strains of the species *Lactococcus lactis* and *Streptococcus thermophilus*. Other interesting prokaryotes are bacteria belonging to the genera *Escherichia*, *Zymomonas*, *Bacillus* and *Pseudomonas*, in particular the species *Escherichia coli*, *Zymomonas mobilis*, *Bacillus subtilis* and *Pseudomonas putida*.

In an expedient manner of carrying out the method according to the invention the cell is transformed or transfected with an expression vector including DNA encoding F₁ or a portion thereof exhibiting ATPase activity under the control of a promoter functioning in said cell, and said DNA is expressed in the cell. Said DNA encoding F₁ or a portion thereof may be derived from a prokaryotic or a eukaryotic organism, and it may be either homologous or heterologous to said cell.

The F₁ part of the bacterial H⁺-ATPase complex consists of several subunits that together are responsible for catalyzing ATP hydrolysis: the β -subunit is thought to carry the actual hydrolytic site for ATP hydrolysis, but

in vitro ATPase activity requires that the β -subunit forms a complex together with the α - and γ -subunit ($\alpha_3\gamma\beta_3$). The activity of this complex is modulated by the ϵ -subunit, so that the *in vitro* activity of the $\alpha_3\gamma\beta_3\epsilon$ complex is five fold less than the $\alpha_3\gamma\beta_3$ complex.

In a specific embodiment of the method according to the invention said DNA encoding F_1 or a catalytic active portion thereof, is derived from *Escherichia coli*, *Streptococcus thermophilus* or *Lactococcus lactis* and is selected from the group consisting of the gene encoding the F_1 subunit β or a catalytically active portion thereof and various combinations of said gene or portion with the genes encoding the F_1 subunits δ , α , γ and ϵ or catalytically active portions thereof.

In particular said DNA encoding F_1 or a portion thereof may be selected from the group consisting of the *Escherichia coli*, *Streptococcus thermophilus* and *Lactococcus lactis* genes *atpHAGDC* (coding for subunits δ , α , γ , β , ϵ), *atpAGDC* (coding for subunits α , γ , β , ϵ), *atpAGD* (coding for subunits α , γ , β), *atpDC* (coding for subunits β , ϵ) and *atpD* (coding for subunit β alone).

Particularly interesting eukaryotes are the yeasts *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei*, and the DNA encoding F_1 or a portion thereof may be derived from such organisms and is selected from the group consisting of the gene encoding the F_1 subunit β or a portion thereof and various combinations of said gene or portion with the genes encoding the other F_1 subunits or portions thereof.

Vectors including DNA encoding the soluble part (F_1) of the membrane bound (F_0F_1 type) H^+ -ATPase or a portion of F_1 exhibiting ATPase activity, derived from the lactic acid bacteria *Lactococcus lactis* and *Streptococcus ther-*

mophilus and from the yeasts *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* are also comprised by the invention as well as expression vectors including such DNA under the control of a promoter capable
5 of directing the expression of said DNA in a prokaryotic or eukaryotic cell.

Specific vectors according to the invention are plasmids including DNA encoding the soluble part (F_1) of the membrane bound (F_0F_1 type) H^+ -ATPase or a portion of F_1 exhibiting ATPase activity, said DNA being derived from
10 *Lactococcus lactis* subsp. *cremoris* (SEQ ID No. 1), *Lactococcus lactis* subsp. *lactis* (SEQ ID No. 6), *Streptococcus thermophilus* (SEQ ID No. 10), *Phaffia rhodozyma* (SEQ ID
15 No. 14), and *Trichoderma reesei* (SEQ ID No. 16).

Further, the invention provides a method of optimizing the formation of biomass or a desired product by a cell, the method being characterized by expressing different
20 levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate
25 is optimized.

Often, but not always, the optimization of a given product flux produced by a cell will entail the attainment of either maximum or minimum conversion rate of a substrate.

30

In an expedient manner of practicing this method of the invention a number of specimens of said cell are transformed or transfected with their respective expression vector each including DNA encoding a different portion of
35 the cytoplasmic part (F_1) of the membrane bound (F_0F_1 type) H^+ -ATPase up to and including the entire F_1 , each portion exhibiting ATPase activity, said DNA in each ex-

pression vector being under the control of a promoter functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product in each specimen, and choosing a specimen yielding an optimal conversion rate. In a particular embodiment of this manner, which is especially suited for scientific studies, the promoter in each expression vector is an inducible promoter, and each cell specimen is grown at different concentrations of inducer in order to fine-tune the optimal conversion rate.

In a preferred manner of practicing the above method of optimizing the performance of a cell a number of specimens of said cell are transformed or transfected with their respective expression vector including DNA encoding a portion of the cytoplasmic part (F₁) of the membrane bound (F₀F₁ type) H⁺-ATPase up to and including the entire F₁, said portion exhibiting ATPase activity, said DNA in the respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimal conversion rate. In a more preferred embodiment of this manner, which is well suited to establish an optimal production strain, the respective expression vectors include DNA encoding different such portions of F₁ up to and including the entire F₁, each DNA in respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell.

35

Also in this method of the invention the DNA encoding a portion of F₁ up to and including the entire F₁ may be

derived from a prokaryotic or a eukaryotic organism, and it may be either homologous or heterologous to said organism. The specific DNAs mentioned above may also conveniently be employed in this method.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. A linear representation of the plasmids constructed for modulating the cellular [ATP]/[ADP] ratio in *E. coli* (not drawn to scale).

Figure 2. Effect of induction of F₁-ATPase activity on the growth of *E. coli* in batch culture. Cells were grown for more than 10 generations in minimal medium supplemented with glucose (0.4 g/l), ampicillin (0.1 g/l) and the indicated concentration of inducer, IPTG.

Figure 3. Effect of ATPase expression on the intracellular concentration of ATP and ADP (concentration in arbitrary units), and on the ratio [ATP]/[ADP].

Figure 4 Effect of increased ATPase expression on the glycolytic flux.

DETAILED DESCRIPTION OF THE INVENTION

Many biosynthetic reactions in the living cell (anabolism), require an input of free energy (ATP), which is generated through a series of degrading reactions (catabolism). In the aerobic cell, there are two routes for ATP synthesis: 1) substrate level phosphorylation, where an energy rich phosphoryl group is transferred directly from a high energy intermediate metabolite to ADP, and 2) oxidative phosphorylation, where the free energy is first transformed into redox free energy by oxidizing the energy source, then into a proton gradient by respiration and finally the proton gradient is used by the H⁺-ATPase

to drive ATP synthesis from ADP and inorganic phosphate. In other cases, e.g. anaerobic growth, there is only the first route, substrate level phosphorylation, that can be used for ATP synthesis. An example hereof is the homolactic LAB, where lactose is converted through the glycolytic pathway to lactic acid, which is excreted from the cells and thereby lowers the pH of the growth medium (usually milk products). With respect to ATP generation, homolactic fermentation is a very inefficient process, and only four moles of ATP are produced from 1 mole of lactose through substrate level phosphorylation.

The anabolic (ATP consuming) and catabolic (ATP producing) fluxes are normally well balanced in the living cell, and therefore, in the wild-type cell under normal growth conditions, the catabolic fluxes will be proportional to the anabolic fluxes. If a reaction is introduced that for instance hydrolyzes ATP in the cell and thereby lowers the cellular energy state (i.e. the $[ATP]/[ADP]$ ratio), then either catabolism should increase or anabolism (growth) should decrease in order to make the consumption rate equal the production rate again. Which of these two scenarios will take place depends on whether, initially, the growth rate of the cell is limited through anabolism or through catabolism, i.e. whether there is a surplus or a shortage of energy in the cell to begin with. If there is a shortage of energy, then the rate of the anabolic reactions is limited by catabolism and these reactions will be sensitive to changes in the cellular energy state. Introduction of an ATP-hydrolyzing reaction is then most likely to affect the growth rate of the cells. On the other hand, if there is a surplus of energy, then the growth rate will be limited mainly by the anabolic reactions; the rate of anabolism will be insensitive to a decrease in the energy state, but the catabolic rate may increase due to a decrease in product inhibition at lower $[ATP]/[ADP]$ ratio.

In vitro, the F₁ part of the H⁺-ATPase complex has been shown to have ATPase activity, see above. But so far nobody has managed to use the F₁ complex to stimulate the glycolytic flux, or even to show that the F₁ complex can hydrolyze ATP in intact cells. Indeed, when we first tried to overexpress the F₁ complex, consisting of the genes for the subunits α , γ , β and ϵ , this had virtually no effect on the growth of *E. coli*, even when the genes were transcribed from the maximally induced *tac* promoter and on a very high copy number vector (derived from pUC18). One skilled in the art of gene expression in *E. coli* will appreciate that this combination is one of the most efficient expression systems that exists for this organism.

We then decided to try to express different combinations of subunits of the F₁ complex, in order to see if other combinations of subunits would be more powerful. Plasmids were constructed containing various combinations of the genes encoding the F₁ part of the bacterial F₁F₀-ATPase complex from *E. coli*. The genes were expressed, either from an inducible (*lac*-type) promoter at various concentrations of inducer or from a series of constitutive promoters of varying promoter activity. These plasmids should express various levels of ATPase activity when introduced into the bacterial cell. Depending on which F₁ genes are present on the plasmid and the strength of the promoter which is used to drive the expression, we observed various degrees of inhibition of the growth of the cells harbouring these plasmids. Surprisingly, the beta subunit alone and in combination with the epsilon subunit turned out to be far more active *in vivo* than the entire F₁ complex.

The objective of this work was to affect the energy state of the cells, as reflected in the ratio [ATP]/[ADP]. We therefore measured the intracellular concentration of ATP

and ADP in growing cells expressing various activities of F₁-ATPase. Indeed the ATP concentration decreased slightly with increasing ATPase activity and the ADP concentration increased, and therefore the [ATP]/[ADP] ratio decreased (the effect on the ATP concentration was less than the effect on the ADP concentration as expected, see above). We also calculated the glycolytic flux through the cells with various levels of ATPase activity. We found that the flux through the glycolytic pathway was first stimulated with increasing expression of ATPase activity, until a certain (optimal) ATPase activity which gave maximal glycolytic flux. Further increase of ATPase expression resulted in a lower glycolytic flux, due to a secondary effect of the ATPase activity on the growth of the cells. This emphasizes the need for optimization of gene expression rather than merely overexpressing the genes.

EXAMPLE 1

ATP hydrolysis and enhanced glycolytic flux in *Escherichia coli*, using an inducible promoter

Restriction enzymes, T4 DNA polymerase, calf intestine phosphatase (CIP) were obtained from Pharmacia.

Procedures for DNA isolation, cutting with restriction enzymes, filling in sticky DNA ends with T4 DNA polymerase in the presence of dATP, dCTP, dGTP and dTTP, treatment with calf intestine phosphatase to remove phosphate groups from 5' DNA ends and ligation of DNA fragments are carried out by standard methods as described by Maniatis et al., 1982.

Extraction and measurement of ATP and ADP

0.9 ml of cell culture was mixed with 0.9 ml of (80 °C) phenol (equilibrated with 10 mM Tris, 1 mM EDTA pH=8) and immediately vortexed vigorously for 10 seconds. After 1 hour at room temperature the sample was vortexed again for 10 seconds and the two phases were separated by centrifugation at 14000 rpm for 15 minutes, and then residual phenol in the water phase was removed by extraction with 1 volume of chloroform. ATP and ADP concentrations were then measured, using a luciferin-luciferase ATP monitoring kit (obtained from and used as recommended by LKB, except that 3 mM of phosphoenol-pyruvate was added). [ATP] was measured first. Subsequently the ADP in the same sample was converted to ATP by adding pyruvate kinase, and [ADP] was recorded as the concomitant increase in luminescence.

Construction of plasmids carrying combinations of the *E. coli atp* genes

The following combinations of *E. coli* genes coding for F₁ subunits were chosen for expressing ATPase activity in *E. coli*: 1. *atpAGDC* (subunits α , γ , β , ϵ), 2. *atpAGD* (subunits α , γ , β), 3. *atpDC* (subunits β , ϵ), and 4. *atpD* (subunit β alone).

Cloning of fragments carrying *atp* genes onto pUC19

The plasmid pBJC917 (von Meyenburg, K., et al., 1984) which carries the entire *atp* operon was cut with

1) the restriction enzyme *DraIII*, and a 5009 bp DNA fragment containing the *atpAGDC* genes was isolated;

2) the restriction enzymes *DraIII* and *Tth1111*, and a 4106 bp DNA fragment containing the *atpAGD* genes was isolated;

3) the restriction enzymes *DraIII* and *SacII*, and a 2364 bp DNA fragment containing the *atpDC* genes was isolated;

4) the restriction enzymes *AvaI* and *Tth111I*, and a 1472 bp DNA fragment containing the *atpD* gene was isolated.

In all four cases the fragments were then treated with T4 DNA polymerase to create blunt ends, and subsequently the fragments were ligated into the cloning vector pUC19 (Yanisch-Perron et al., 1985) which had been cut with *SmaI* and treated with CIP.

The four ligation mixtures were transformed into the *E. coli* strain JM105 (Yanisch-Perron et al., 1985), and the transformation mixtures were plated on LB (Luria-Bertani broth; Maniatis et al., 1982) plates containing 100 µg/ml ampicillin and 75 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal). In this strain background (JM105), plasmids formed by religation of pUC19 will give blue colonies, whereas plasmids that carry foreign DNA fragments inserted into the *SmaI* site of pUC19, will give white colonies. A number of white colonies from the four transformations were therefore picked for further analysis: plasmid DNA was isolated and analysed by cutting with various restriction enzymes. Clones were identified from each of the four series which had the desired fragment inserted into the *SmaI* site of pUC19, and in the proper orientation. These four plasmids were named, respectively: pATP-AGDC, pATP-AGD, pATP-DC and pATP-D, with reference to the specific *atp* genes carried by the plasmid.

Cloning combinations of the *atp* genes under the control of an inducible (*tac*) promoter

In order to be able to control the expression of the ATPase activity, we selected the expression vector pTTQ18

(Starck, 1987). This vector is a derivative of pUC18 (Yanisch-Perron *et al.*, 1985), which carries a *tac* promoter and the lactose repressor gene, *lacI*. Immediately downstream of the *tac* promoter is a multiple cloning site (MCS; the polylinker from pUC18) in which genes can be inserted to be expressed from the *tac* promoter. The *tac* promoter is of the *lac*-type, i.e. repressed by the lactose repressor and inducible with isopropyl- β -D-thiogalactoside (IPTG).

10

The four plasmids, pATP-AGDC, pATP-AGD, pATP-DC and pATP-D were cut with *KpnI* and *XbaI*, which gave the four DNA fragments, 5023, 4120, 2378 and 1486 respectively. After purification, the fragments were ligated into the cloning vector, pTTQ18, which had also been cut with *KpnI* and *XbaI* (see figure 1). The ligation mixtures were transformed into *E. coli* K-12 MC1000 (Casabadian and Cohen, 1980), and the transformation mixtures were plated on LB plates containing 100 μ g/ml ampicillin. A number of colonies from the four transformations were therefore picked for further analysis: plasmid DNA was isolated and analysed by cutting with various restriction enzymes. Clones were identified from each of the four series which had the desired fragment inserted into the MCS of pTTQ18 in the proper orientation. These four plasmids were named, respectively: pTAC-AGDC, pTAC-AGD, pTAC-DC and pTAC-D, with reference to the specific *atp* genes carried by these plasmid and the *tac* promoter used for their expression. For the purpose of subsequent physiological studies, the plasmids were transformed into the *E. coli* K-12 strain LM3118, which is used routinely for physiological experiments in this laboratory. The corresponding names for the LM3118 strain carrying these four plasmids are PJ4332, PJ4333, PJ4335 and PJ4334, respectively.

35

Effect of induction of ATPase activity on the growth of *E. coli* on plates

The strains containing the four plasmids were streaked on LB plates containing ampicillin (100 µg/ml) and 1 mM of IPTG which should give maximum expression from the *tac* promoter. Table I shows how the four strains responded: the strain carrying plasmid pATP-AGDC, which contains the genes for the four subunits, α , γ , β and ϵ , was only very slightly affected in growth, even in the presence of 1 mM IPTG. The other three plasmids, pTAC-AGD, pTAC-DC and pTAC-D caused severe growth inhibition in the presence of 1 mM IPTG, where colonies were no longer visible. With intermediate concentrations of IPTG, 0.01 mM and 0.1 mM, the plasmids affected the growth of their host cells to different extents: pTAC-AGD was the most active, giving rise to a strong inhibition of growth already with 0.01 mM IPTG, a concentration which gave only a slight inhibition with the plasmid pTAC-DC and no inhibition of the strain with pTAC-D. With 0.1 mM IPTG, colonies were hardly visible for the strain that carried the pTAC-AGD, the plasmid pTAC-DC caused strong growth inhibition, whereas the effect of pTAC-D was significant but small.

Table I

Strain	Plasmid	- IPTG	0.01 mM IPTG	0.1 mM IPTG	1 mM IPTG
PJ4332	pTAC-AGDC	++++	++++	++++	+++
PJ4333	pTAC-AGD	++++	++	+	-
PJ4335	pTAC-DC	++++	+++	+	-
PJ4334	pTAC-D	++++	++++	++	-

++++ = normal colony size; +++ = slight inhibition; ++ = 1/2 normal size; + = 1/10 normal size; - = no growth

The effect of ATPase expression from the four plasmids above was also studied in the *E. coli* mutant LM3115, in which the entire *atp* operon on the chromosome is deleted, but which grows with almost wild-type growth rate on LB

medium. With this strain transformed with the four plasmids we observed a similar pattern of growth inhibition on LB plates as a function of IPTG concentration. This shows that the effect of ATPase expression was independent of the presence of the normal *atp* operon.

Effect of induction of ATPase activity on the growth of *E. coli* in liquid cultures

The effect of induction of ATPase was also studied with cells grown in liquid cultures. For this purpose we chose the strain PJ4333, carrying the plasmid pTAC-AGD, because this plasmid appears to be the most active with respect to the inhibitory effect on the growth of *E. coli*. Figure 2 shows the growth of PJ4333 in minimal medium supplemented with a limiting concentration of glucose (0.4 g/l) and ampicillin (0.1 g/l), without IPTG and in the presence of increasing concentrations of IPTG. We observed that the growth rate of the strain was practically constant (within some 10%) with increasing amounts of IPTG up to about 30 μ M. At higher than 40 μ M IPTG, the growth of the cells were slightly inhibited, in accordance with the experiments on plates, see above.

However, what was affected was the final density of cells that one obtains from the limited amount of glucose that was included in each culture: The more ATPase that is expressed in the cells, the lower the yield of cell mass. Apparently, the cells become less economic with respect to converting the glucose into biomass, or in other words *they consume more glucose per cell synthesized*. If this is due to the expression of ATPase activity, then we would expect to see an effect hereof on the energy state of the cells. We therefore measured the concentrations of ATP and ADP in the cells growing with different expression levels of ATPase activity.

Indeed, the intracellular ATP concentration decreased gradually and the ADP concentration increased, with increased expression of ATPase; therefore the $[ATP]/[ADP]$ ratio decreased with increased expression of ATPase, which imply that the increased glucose consumption is the result of increased ATP conversion to ADP, see figure 3. The actual flux of glucose through the cells (J_{gluc} , mmol glucose / g cell dry weight / hour) is also interesting, because this value tells us whether the performance of the cell increased as the ATPase activity increased. J_{gluc} can be calculated from the yield, Y (g cell dry weight / mol glucose) and the specific growth rate of the culture, μ (1/hours):

$$J_{gluc} = \mu/Y$$

Figure 4 shows how the flux of glucose changed as the activity of ATPase increased: the glycolytic flux increased gradually as the ATPase expression increased, until a maximum was reached (at 30 μM IPTG). Further increase of ATPase expression had a slightly negative effect on the glucose flux. This was probably because the energy state of the cells became so low that this had a negative effect on some anabolic reactions, since the growth rate was lower for the culture that was grown in the presence of 40 μM IPTG.

The expression of subunits of the F_1 part of the bacterial H^+ -ATPase lowers the energy state of the bacterial cell. This is due to hydrolysis of ATP into ADP and P_i . The expression of ATPase activity does not affect the growth rate of *E. coli* much at low levels of expression, but the efficiency by which the substrate is converted into biomass was strongly reduced. Under the set of conditions used here, the expression of ATPase activity has a stimulatory effect on the rate by which the cells consumes the exogenous glucose.

EXAMPLE 2

Expression of F₁-ATPase activity from constitutive promoters in *E. coli*

5

In example 1 we used a *lac*-type promoter system to modulate the expression of the F₁ ATPase subunits in *E. coli*. However, for the optimization of gene expression for instance in industrial bioreactors or for the use in fermented food products, the use of *lac* type promoters is not always feasible. In this example we illustrate the optimization of F₁-ATPase expression in *E. coli*, using a series of constitutive promoters of different strength, to control the expression of the *atpAGD* genes which here originates from *E. coli*. The constitutive promoters (CP promoters) were selected from a library of artificial promoters which had previously been cloned onto a shuttle vector for *E. coli* and *L. lactis*, pAK80 (Israelsen, et al., 1995) as described in our co-pending PCT patent application PCT/DK97/00342. The selected plasmid derivatives of pAK80 were pCP34, pCP41 and CP44 (CPX cloning vectors). The *atpAGD* fragment from pTAC-AGD (from example 1) was first subcloned in a polylinker in order to have the *atpAGD* fragment flanked by two *Bam*HI sites. Subsequently, this *Bam*HI fragment was cloned into the unique *Bam*HI site downstream of the CP promoters on the plasmids pCP34, pCP41 and CP44, resulting in the plasmids, pCP34::*atpAGD*, pCP34::*2atpAGD*, pCP41::*atpAGD* and CP44::*atpAGD*, where pCP34::*2atpAGD* contains two *atpAGD* fragments in tandem.

Subsequently, the strains were characterized with respect to growth rate, growth yield and glycolytic flux in glucose minimal medium supplemented with 200 µg/ml erythromycin, essentially as described in example 1, see table 2.

35

The expression of the F₁-ATPase subunits had a slightly negative effect on the growth rate as the expression level increased. The effect on growth yield was much stronger and at the highest expression level the growth yield had dropped to 40 % of the initial value. The glycolytic flux was stimulated 70% at the highest expression level of ATPase, and at this expression level the growth rate was lowered by 30%.

Table 2. Effect of expression of uncoupled F₁-ATPase activity (*E. coli* α , γ , β subunits) in *E. coli*

Plasmid	Biomass yield gdw/mmol glucose	Growth rate, μ h ⁻¹	Glucose flux mmol glu- cose/h/gdw	Biomass yield %	Growth rate %	Glucose flux
pCP41	0,067	0,47	6,9	100	100	100
pCP41::atpAGD	0,047	0,42	9,1	69	90	131
pCP34	0,063	0,41	6,6	100	100	100
pCP34::atpAGD	0,034	0,34	9,9	54	81	149
pCP44	0,067	0,44	6,5	100	100	100
pCP44::atpAGD	0,027	0,30	11,2	40	69	172

EXAMPLE 3

Expression of *E. coli* F₁-ATPase activity from constitutive promoters in *L. lactis*.

The plasmids from example 2 which express the *E. coli* F₁-ATPase subunits to various extent are also capable of replicating in *L. lactis*, and could therefore be used to test whether the *E. coli* F₁-ATPase subunits can be used to hydrolyse ATP in *L. lactis*.

The plasmids pCP34::*atpAGD*, pCP34::*2atpAGD* and pCP41::*atpAGD*, were transformed into the *L. lactis* subspecies *cremoris* strain, MG1363, which is used routinely for physiological experiments in this laboratory. In addition we transformed the respective vectors, pCP34 and pCP41 in order to have proper control strains. Subsequently, the resulting transformants were characterized with respect to growth rate, growth yield and glycolytic flux, in comparison to the respective vectors, pCP34 and pCP41, by growing the various cultures in defined medium (SA medium) supplemented with a limiting concentration of glucose (0.1%), see table 3.

Table 3. Expression of *E. coli* F₁-ATPase in *L. lactis*

Plasmid	Biomass yield gdw/mmol glucose	Growth rate, μ h ⁻¹	Glucose flux mmol glu- cose/h/gdw	Biomass yield %	Growth rate %	Glucose flux %
pCP34	0,073	0,664	9,161	100	100	100
pCP34:: <i>atpAGD</i>	0,071	0,653	9,230	97,5	98,3	100,8
pCP34:: <i>2atpAGD</i>	0,069	0,655	9,560	94,6	98,7	104,4
pCP41	0,072	0,645	8,925	100	100	100
pCP41:: <i>atpAGD</i>	0,070	0,590	8,461	96,5	91,5	94,8

The results show that the plasmids pCP34::*atpAGD* and pCP34::*2atpAGD* did affect the growth yield and the glycolytic flux to some extent, but the plasmids were far less efficient in *L. lactis*, compared to *E. coli*. This was probably a consequence of a lower expression of the *E. coli* ATPase subunits, or some of these, in *L. lactis*, due to a lower copy number of the pAK80 vector in *L. lactis* (5-10), and due to differences in the translational efficiency of the three individual *atp* genes which originates from *E. coli*. The plasmid pCP41::*atpAGD* also resulted in a lower growth yield, indicating that also in

this case uncoupled ATP hydrolysis was taking place. However, the pCP41::atpAGD plasmid had a relatively strong inhibitory effect on the growth rate and therefore the glycolytic flux was not increased by this plasmid. It is possible that the heterologous expression of *E. coli* ATPase subunits resulted in growth inhibition due to effects other than ATP hydrolysis, e.g. by interfering with the function of the *L. lactis* F₁F₀ H⁺-ATPase complex.

10 **EXAMPLE 4**

Expression of *L. lactis* F₁-ATPase subunits β and ϵ , in *L. lactis*.

15 In the example above we showed that the expression of F₁-ATPase subunits from *E. coli* in *L. lactis*, resulted in only a small stimulation of the glycolytic flux. It is possible that the heterologous expression of *E. coli* ATPase subunits resulted in growth inhibition due to effects other than ATP hydrolysis, e.g. by interfering with the function of the *L. lactis* F₁F₀ H⁺-ATPase complex. In the present example we have expressed the *L. lactis* F₁-ATPase subunits, β and ϵ , in *L. lactis*, as this appeared to be an effective combination of subunits when expressed in *E. coli*, see example 1. The atpDC_{Llc} genes from *L. lactis* subspecies *cremoris* (SEQ ID No. 1) was cloned on a 2.5kb HindIII fragment into the HindIII restriction site on the standard cloning vector, pBluescript, into *E. coli* K-12, strain BOE270. Subsequently, the atpDC_{Llc} genes were cut out on a 2.5kb BamHI-SalI fragment and cloned into 5 expression vectors, pCP32, pCP34, pCP37, pCP41 and pCP44 which had been digested with BamHI and SalI, resulting in the plasmids pCP32::atpDC_{Llc}, pCP34::atpDC_{Llc}, pCP37::atpDC_{Llc}, pCP41::atpDC_{Llc} and pCP44::atpDC_{Llc}, respectively, where the lacLM genes downstream of the CP promoters, have been replaced with the atpDC_{Llc} genes. These plasmids should express the *L. lactis* F₁-ATPase

subunits, β and ϵ , to different extent. The plasmids were then transformed into MG1363 with selection for the erythromycin resistance carried by these vectors. Experiments were then performed to test whether the constructs

5 resulted in conversion of ATP into ADP in *L. lactis*. The strains carrying the different constructs was then grown in GM17 medium supplemented with 5 μ g/ml erythromycin. The plasmids did not have a strong effect on the growth rate of the cultures, which remained close to the growth

10 rate of the respective vector control plasmids. The yield of biomass, however, decreases for all the cultures by up to 17%, which shows that the cultures did indeed express uncoupled ATPase activity, see table 4.

15 **Table 4.** Effect of expression of *L. lactis* β and ϵ subunits on acid production by *L. lactis*, at 30°C and with initial pH 6.7.

Plasmid	Biomass ^a OD ₄₅₀	Final pH ^a	Acid formation, relative to biomass ^a % of vector
pCP34	5.08	4.27	100
pCP34::atpDC11c	4.72	4.31	98.0
pCP41	4.66	4.34	100
pCP41::atpDC11c	5.21	4.24	113.5
pCP37	4.89	4.28	100
pCP37::atpDC11c	4.63	4.24	116.1
pCP32	4.86	4.34	100
pCP32::atpDC11c	3.95	4.36	116.9

20 Each value is the average of 3-4 independent cultures. The acid production was calculated from the pH change, and normalized by the biomass produced.

The GM17 growth medium used in these experiments contains a surplus of glucose (1%), and growth only stops when the

25 pH of the growth medium becomes lower than approximately pH 4.3. To some extent, this mimics the situation that the lactic acid bacteria experience during cheese and

yougurt production. In this medium, the growth yield, in terms of the final cell mass of the cultures, reflects the acid production by these cultures.

- 5 In these cultures, the expression of F₁-ATPase subunits will increase three fold at approximately OD600 equal to 1.5. This is a consequence of the three fold amplification of the plasmid copy number that has been shown to take place at this point of the growth curve. In reality,
10 the effect of expressing the F₁-ATPase subunits may therefore be larger.

To test this hypothesis, we grew some of the strains which expressed the *L. lactis* F₁-ATPase subunits β and ϵ
15 in batch cultures of GM17 medium which had been adjusted to pH 5.9, see Table 5. In addition, the temperature of the growth medium may also affect the plasmid copy number and thus the expression of the F₁-ATPase subunits. The experiments were therefore performed at 37°C.

20

Table 5. Effect of expression of *L. lactis* β and ϵ subunits on acid production by *L. lactis*, at 37°C and with initial pH 5.9.

Plasmid	Biomass ^a OD ₄₅₀	Ffinal pH ^a	Acid formation, relative to biomass ^a % of vector
pCP34	1.24	4.95	100
pCP34::atpDC _{11c}	1.06	4.87	141.4
pCP37	1.00	4.96	100
pCP37::atpDC _{11c}	0.58	4.92	188.4

25

Clearly, the effect of the F₁-ATPase activity was much stronger under these growth conditions: the amount of acid produced was almost doubled for the strain carrying the plasmid pCP37::atpDC_{11c}.

30

EXAMPLE 5

Expression of the F₁-ATPase subunits, α , γ , and β , from
L. lactis subspecies *cremoris* in *L. lactis* subspecies
5 *cremoris*.

In example 4, only the *L. lactis* F₁-ATPase β and ϵ
subunits were expressed in *L. lactis*. However, from the
experiments with *E. coli* (example 1), we know that the
10 simultaneous expression of subunits α , γ , and β , is a
more powerful combination, which could also be the case
for *L. lactis*. In order to obtain the same strong stimu-
lation of the glycolytic flux and acid production in *L.*
lactis, a set of vectors similar to the vectors described
15 in example 4 was constructed, in which the *atpAGD_{Llc}*
genes derived from *L. lactis*, encoding the subunits α , γ ,
and β (SEQ ID No. 1) was expressed from CP promoters with
different activities. The *atpAGD_{Llc}* genes from *L. lactis*
was cloned on a 2.5 kb *Bam*HI-*Sal*I fragment into the 5
20 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting
in the plasmids, pCP32::*atpAGD_{Llc}*, pCP34::*atpAGD_{Llc}*,
pCP37::*atpAGD_{Llc}*, pCP41::*atpAGD_{Llc}*, pCP44::*atpAGD_{Llc}*, re-
spectively, where the *lacLM* genes downstream of the CP
promoters, has been replaced with the *atpAGD_{Llc}* genes.
25 These plasmids will express the *L. lactis* F₁-ATPase
subunits α , γ , and β , to different extent. The plasmids
were transformed into MG1363 with selection for the
Erythromycin resistance carried by these vectors. Experi-
ments were then performed to show that the constructs
30 were effective in ATP hydrolysis in *L. lactis* and to what
extent the glycolytic flux was enhanced, by growing the
five different constructs in GM17 medium supplemented
with erythromycin, and measuring the growth rate, ATP and
ADP concentrations, the yield of biomass and the rate of
35 acid production.

EXAMPLE 6

Expression of F₁-ATPase subunits from *L. lactis* subsp *lactis*, in *L. lactis* subspecies *lactis*.

5

In the examples 3-5 above, we used the strain *L. lactis* subsp. *cremoris*, MG1363. This strain is plasmid-free and is used routinely in our laboratory as a simple model organism for our physiological studies. But strains belonging to the subspecies *lactis* are also important in cheese production. We therefore cloned and sequenced the *atpAGD_{L11}* genes from *L. lactis* subsp. *lactis*, (SEQ ID No. 6). Subsequently, a 4.2 kb fragment harbouring the *atpAGD_{L11}* genes was cloned into 5 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting in the plasmids, pCP32::*atpAGD_{L11}*, pCP34::*atpAGD_{L11}*, pCP37::*atpAGD_{L11}*, pCP41::*atpAGD_{L11}*, pCP44::*atpAGD_{L11}*, respectively. These plasmids were then transformed into *L. lactis* subsp. *lactis* as described in example 3. The resulting strains with different expression levels of the F₁-ATPase subunits α , γ and β were then used to characterize the effect hereof on the growth yield, growth rate, glycolytic flux, and the cellular energy state of *L. lactis* subsp. *lactis*, as described in the examples 1-5.

25

EXAMPLE 7

Expression of F₁-ATPase subunits from *S. thermophilus*, ST3, in *S. thermophilus*, ST3

30

In the examples 3-6 above, we used strains of the genus *Lactococcus*. These strains are important in cheese production. As starter cultures for yougurt production, the dairy industry often uses strains of *S. thermophilus*. We therefore cloned and sequenced the *atpAGD_{St}* genes from *S. thermophilus*, strain ST3 (SEQ ID No. 10). Subsequently, a 4.2 kb fragment harbouring the *atpAGD_{St}* genes was cloned

35

into the 5 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting in the plasmids, pCP32::atpAGDSt, pCP34::atpAGDSt, pCP37::atpAGDSt, pCP41::atpAGDSt, pCP44::atpAGDSt, respectively. These plasmids were then transformed into *S. thermophilus* strain ST3. The resulting strains have different expression levels of the F₁-ATPase subunits α , γ , and β , and were then used to characterize the effect hereof on the growth yield, growth rate, glycolytic flux, and the cellular energy state of *S. thermophilus*, as described in the previous examples.

EXAMPLE 8

Expression of a truncated F₁-ATPase β subunit from *Phaffia rhodozyma* in *Saccharomyces cerevisiae*

In this example we show that uncoupled F₁-ATPase expression can also be used to hydrolyze ATP in yeast cells of *Saccharomyces cerevisiae*.

20

A cDNA gene library was prepared from total RNA, isolated from *Phaffia rhodozyma*, by cloning the cDNA fragments into the expression vector, pYES2.0. One of the resulting plasmids, pATPbeta, gave rise to an ade⁺ phenotype in the *Saccharomyces cerevisiae* strain, W301, which carries a mutation in the ADE2 gene. Sequencing of the clone revealed a 0.9 kb insert, which encoded a protein of 254 amino acids (SEQ ID No. 14). The encoded protein had a very high homology to the C-terminal part of F₁-ATPase β subunits from other organisms, prokaryotic as well as eukaryotic, including the β subunit from *S. cerevisiae* (86% identity).

The ADE2 mutation results in starvation for an intermediate further down in the purine metabolism, AICAR (which under normal conditions is produced by ADE3, two steps further down in this pathway). AICAR is essential for de

novo biosynthesis of AMP and GMP, and *ADE2* mutants therefore need an alternative purine source in the growth medium. However, there is an alternative route for synthesis of AICAR which involves some of the genes involved in histidine biosynthesis. These genes are normally repressed under the conditions used for the complementation, but when the *HIS3* gene is introduced on a plasmid, this complements the *ADE2* mutation because the cells start to produce AICAR. Since AICAR is a precursor for ATP, it is likely that a lack of ATP (or increased levels of ADP and AMP) provide a signal to derepress the *HIS3* gene and generate AICAR (which will subsequently end up as ATP). Indeed, cross-pathway regulation between purine and histidine biosynthesis has been found in yeast and involves the transcription factors *BAS1* and *BAS2*. A reasonable explanation for the *ade'* phenotype conferred by the plasmid, is therefore that the plasmid gives rise to ATP hydrolysis in the cytoplasm, thereby effecting the concentrations of adenine nucleotides in the cytoplasm.

Importantly, this truncated β subunit from *Phaffia rhodozyma* that was encoded on *pATPbeta*, included the region of the β subunit which is thought to encode the catalytic site for ATP hydrolysis. The truncation of the N-terminal part of the β subunit probably means that the protein will no longer be exported into the mitochondrion, but should stay within the yeast cytoplasm.

The truncated β subunit *pATPbeta* is expressed from a *gal* promoter, i.e. it can be induced with galactose. If the truncated β subunit encoded by the clone is active in ATP hydrolysis it should result in a decrease in the growth yield, and at sufficiently high expression level, we should also observe inhibition of growth. The strain which expressed the truncated β subunit and a control strain (which contained a plasmid *pHIS3* containing a *HIS3* gene from *Phaffia rhodozyma*), were streaked on plates

containing galactose as the energy source, which will give maximal expression of the truncated β subunit. Indeed, the growth of the strain which expressed the truncated β subunit was strongly inhibited by the presence of galactose, whereas the control strain grew normally. As a control, the growth of the two strains were also compared on a plate containing glucose as the energy source, conditions under which the expression of the β subunit should be repressed, and indeed we observed little difference in growth of the two strains on these plates, see table 6.

Subsequently, for the purpose of the physiological investigations, the two strains were converted into Rho^- strains (petit mutants, defective in oxidative phosphorylation) by standard treatment with ethidium bromide. The induction with galactose caused even stronger inhibition of growth in the Rho^- background, which further indicates that the cause of the growth inhibition is uncoupled ATP hydrolysis in the cytoplasm.

Table 6. Effect of expression of a truncated F_1 -ATPase β subunit from *Phaffia rhodozyma* in *S. cerevisiae* on SC plates

Strain/plasmid	SC-ura + glucose	SC-ura + galactose
Rho^+ /pATPbeta	+++++	+
Rho^+ /pHIS3	++++	+++
Rho^- /pATPbeta	+++++	-
Rho^- /pHIS3	++++	+++

Growth experiments were performed to measure the resulting changes in the ATP/ADP ratio and the degree of stimulation of the glycolytic flux and ethanol formation, essentially as described in the examples above, and to show that the truncated β subunit from *Phaffia rhodozyma* is active with respect to converting ATP into ADP in the yeast cell.

EXAMPLE 9.**Expression of F₁-ATPase β subunit from *Trichoderma reesei* in *Saccharomyces cerevisiae*.**

5

In this example we show that the expression of the F₁-ATPase β subunit from the filamentous fungus, *Trichoderma reesei* can be used to improve the product formation of *Saccharomyces cerevisiae*.

10

The gene encoding the F₁-ATPase β subunit homologue from *Trichoderma reesei* was isolated from a cDNA library, inserted into a multicopy expression vector, pAJ401. DNA sequencing (SEQ ID 16) revealed that the cloned gene had
15 very high homology to the β subunits from *Neurospora crassa* (91% identity), *Kluyveromyces lactis* (68%) and *Saccharomyces cerevisiae* (68%). Importantly, the first 43 amino acids in this β subunit, which encodes the signal for exporting the protein into the mitochondria, was ho-
20 mologous to the N-terminal part of the β subunit from *Neurospora crassa* (58% identity), but not to that of *Saccharomyces cerevisiae*. It is therefore likely that the β subunit from *Trichoderma reesei* will stay within the cytoplasm when expressed in *Saccharomyces cerevisiae*. This
25 is important for the many cases where the fermentation is carried out anaerobically, because in these cases it is probably most efficient if the ATP hydrolysis takes place in the cytoplasm. Alternatively, in those cases where the β subunit is transported into the mitochondrion, it may
30 be useful to genetically modify the β subunit so that it stays within the cytoplasm.

The gene encoding the F₁-ATPase β subunit homologue from *Trichoderma reesei* was expressed in *S. cerevisiae* strain
35 VW1b (MAT alpha, *leu2-3/112*, *ura3-52*, *trp1-289*, *his3D1*, *MAL2-8c*, *SUC2*). To test whether the presence of the *T. reesei* β subunit resulted in ATP hydrolysis in the cyto-

plasm of the *Saccharomyces cerevisiae* host cells, we measured the intracellular concentrations of ATP, ADP and AMP, under various growth conditions in cultures of two strains expressing the β subunit (pATP β 34 and pATP β 44) and a strain carrying the vector plasmid, pFL60, see table 7.

Table 7. Effect of expression of *T. reesei* β subunit on ATP, ADP and AMP concentrations in *S. cerevisiae*

Strain	ATP $\mu\text{mol/gdw}$	ADP $\mu\text{mol/gdw}$	AMP $\mu\text{mol/gdw}$	ATP/ADP ratio
<i>Aerobic/exp.phase</i>				
pATP β 34	19.3	5.58	3.31	3.5
pATP β 44	13.9	5.15	3.25	2.7
pVECTOR	16.6	5.47	3.43	3.0
<i>Aerobic/stat.phase</i>				
pATP β 34	9.30	4.03	2.89	2.3
pATP β 44	8.99	3.90	2.42	2.3
pVECTOR	19.5	4.62	2.87	4.2
<i>anaerobic/stat.phase</i>				
pATP β 34	4.39	11.6	6.72	0.4
pATP β 44	3.14	10.5	6.65	0.3
pVECTOR	8.84	10.2	6.37	0.9

* according to Bergmeyer (1985)

The β subunit did not appear to have a significant effect on the concentrations of ATP, ADP and AMP in cells growing on glucose in the exponential growth phase. The reason is probably that the ATP concentration that the homeostatic control of ATP synthesis can here keep up with the extra drain on ATP conferred by the β subunit F_1 -ATPase activity. Indeed, the growth rate of these cultures was unaffected by the presence of the F_1 -ATPase activity, see table 7. But in the stationary cultures the concentration of ATP decreased significantly in the cultures expressing the β subunit, compared to the control. The effect was strongest in the anaerobically grown cultures where the ATP was lowered by a factor of 2-3. In these cultures, ATP must be generated through oxidative phosphorylation, (which is not even an option for the an-

aerobic cultures), and any effect of uncoupled ATP hydrolysis should therefore indeed be stronger in these cells.

5 **Shake flask cultivations of cultures expressing the F_1 -ATPase β subunit homologue in *Saccharomyces cerevisiae*.**

Shake flask cultivations were performed under microaerobic/anaerobic conditions with volume ratio 1/1.25 and no
 10 agitation; with 400 ml growth media in 500 ml Erlenmeyers on magnetic stirring. The growth media contained 5 g/l of glucose and amino acids and bases according to synthetic complete medium (SC-ura+0.5%G). OD_{600} was monitored during the cultivation ($OD_{600}=1.0$ is equal to 0.3 g/l dry
 15 weight). Ethanol and glucose were measured with HPLC (Waters, Sugar-Pak or IC-Pak columns). Production of ethanol (grams of ethanol per grams of cell dry weight) is shown in Table 8.

20 **Table 8.** Effect of expression of *T. reesei* β subunit, on fluxes of ethanol and glucose in *S. cerevisiae*

Strain	μ h^{-1}	J_{gluc} g/h/gdw	J_{etoh} g/h/gdw	J_{gluc} relative to control	J_{etoh} relative to control
pATP β 34	0.40	2.811	1.190	107.7	105.6
pATP β 44	0.40	2.750	1.187	105.3	105.3
pVECTOR control	0.39	2.611	1.127	100	100

These data show that the presence of the *T. reesei* F_1 -
 25 ATPase β subunit resulted in an increased flux of glucose, as well as ethanol, in the *Saccharomyces cerevisiae* host cells.

REFERENCES

- Casabadan, M.J., and Cohen, S.N. (1980). *J. Mol. Biol.*, 138, 179-207.
- 5 Israelsen, H. (1995). Cloning and partial characterization of regulated promoters from *Lactococcus lactis* Tn917-lacZ integrants with the new promoter probe vector, pAK80. *Appl. Environ. Microbiol.*, 61, 2540-2547.
- 10 Maniatis, T., Fritsch, E.F., and Sambrook, J., (1982). *Molecular cloning*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- 15 Miller, J.H., (1972). *Experiments in molecular genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- 20 Starck, M.J.R. (1987). Multicopy expression vectors carrying the *lac* repressor gene for regulated high-level expression of genes in *Escherichia coli*. *Gene* 51, 255-267.
- 25 von Meyenburg, K., Joergensen, B.B., and van Deurs, B. (1984). Physiological and morphological effects of overproduction of membrane-bound ATP synthase in *Escherichia coli* K-12. *EMBO J.* 3, 1791-1797.
- 30 Yanisch-Perron, C., Vieira, J., and Messing, J. (1985). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 33, 103-109.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Peter Ruhdal JENSEN
- (B) STREET: Soegaardsvej 19
- (C) CITY: Gentofte
- (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): DK-2820

(ii) TITLE OF INVENTION: A method of improving the production of biomass or a desired product from a cell

(iii) NUMBER OF SEQUENCES: 17

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: DK 963/96
- (B) FILING DATE: 06-SEP-1996

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4815 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Lactococcus lactis subsp. cremoris
- (B) STRAIN: MG1363

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 26..550
- (D) OTHER INFORMATION: /codon_start= 26
/product= "ATPase subunit"
/gene= "atpH"
/standard_name= "delta subunit of the F1 portion of the F0F1 ATPase"
/label= delta-subunit

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 742..2241
- (D) OTHER INFORMATION: /codon_start= 742
/product= "ATPase subunit"
/gene= "atpA"
/standard_name= "alpha subunit of the F1 portion"

of the F₀F₁ ATPase"
/label= alpha-subunit

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 2260..3126
(D) OTHER INFORMATION: /codon_start= 2260
/product= "ATPase subunit"
/gene= "atpG"
/standard_name= "gamma subunit of the F₁ portion
of the F₀F₁ ATPase"
/label= gamma-subunit

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 3301..4707
(D) OTHER INFORMATION: /codon_start= 3301
/product= "ATPase subunit"
/gene= "atpD"
/standard_name= "beta subunit of the F₁ portion of
the F₀F₁ ATPase"
/label= beta-subunit

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TATCTCGCTA AGTTAGGAGA ATAAG ATG ACA AAA GTA AAT TCA CAA AAA TAC	52
Met Thr Lys Val Asn Ser Gln Lys Tyr	
1 5	
AGT AAA GCT TTA CTT GAG GTC GCC CGA GAA AAA GGA CAA CTT GAA GCA	100
Ser Lys Ala Leu Leu Glu Val Ala Arg Glu Lys Gly Gln Leu Glu Ala	
10 15 20 25	
ATT CTT ACT GAA GTT AGC GAA ATG ATT CAG CTT TTC AAA GAA AAT AAC	148
Ile Leu Thr Glu Val Ser Glu Met Ile Gln Leu Phe Lys Glu Asn Asn	
30 35 40	
TTA GGT GCT TTT TTA GCA AAT GAA GTT TAT TCA TTC TCT GCT AAA TCT	196
Leu Gly Ala Phe Leu Ala Asn Glu Val Tyr Ser Phe Ser Ala Lys Ser	
45 50 55	
GAA TTG ATT GAT ACT TTG CTT CAA ACT TCA TCA GAA GTG ATG TCA AAT	244
Glu Leu Ile Asp Thr Leu Leu Gln Thr Ser Ser Glu Val Met Ser Asn	
60 65 70	
TTC CTG AAT ACT ATT CGT TCT AAT GGA CGT CTA GCT GAC CTC GGA GAA	292
Phe Leu Asn Thr Ile Arg Ser Asn Gly Arg Leu Ala Asp Leu Gly Glu	
75 80 85	
ATA CTT GAA GAA ACT AAA AAT GCA GCA GAT GAC ATG TTC AAA ATT GCT	340
Ile Leu Glu Glu Thr Lys Asn Ala Ala Asp Asp Met Phe Lys Ile Ala	
90 95 100 105	
GAC GTT GAA GTT GTT TCA AGT ATT GCA TTG TCA GAA GCT CAA ATT GAA	388
Asp Val Glu Val Val Ser Ser Ile Ala Leu Ser Glu Ala Gln Ile Glu	
110 115 120	
AAA TTT AAA GCA ATG GCT AAA TCA AAA TTT GAT TTA AAC GAA GTA ACA	436
Lys Phe Lys Ala Met Ala Lys Ser Lys Phe Asp Leu Asn Glu Val Thr	
125 130 135	

GTA ATT AAT ACA GTC AAT GAA AAA ATT CTC GGA GGA TTC ATT GTG AAC	484
Val Ile Asn Thr Val Asn Glu Lys Ile Leu Gly Gly Phe Ile Val Asn	
140 145 150	
TCT CGT GGA AAA ATT ATT GAC GCC TCA TTA AAA ACA CAA TTG GCT AAA	532
Ser Arg Gly Lys Ile Ile Asp Ala Ser Leu Lys Thr Gln Leu Ala Lys	
155 160 165	
ATC GCC GCT GAA ATC CTC TAATCAGGAT AGAAAAATTT TCTTCCTTTG	580
Ile Ala Ala Glu Ile Leu	
170 175	
TTAAAACTT AGTGGAGAAT TTTTCAAAC CAACTGTTA AACTTTTGAA AACATGCAAA	640
GGTAATTTTA AAACCTTGCTT ATTCATGCTC AAAAAGTATA ACTGCAGTTT AAAGCTAAAT	700
AGCCTTGAAC TAGTAAAAAA TTTCTAGAAG GGAGCATATT T TTG GCA ATT AAA	753
Leu Ala Ile Lys	
1	
GCT AAT GAA ATC AGC TCA CTG ATT AAA AAA CAA ATT GAA AAT TTC ACA	801
Ala Asn Glu Ile Ser Ser Leu Ile Lys Lys Gln Ile Glu Asn Phe Thr	
5 10 15 20	
CCA GAT TTT GAA GTT GCT GAA ACT GGT GTC GTT ACC TAT GTT GGT GAT	849
Pro Asp Phe Glu Val Ala Glu Thr Gly Val Val Thr Tyr Val Gly Asp	
25 30 35	
GGT ATC GCG CGT GCC TAT GGC CTT GAA AAT GCG ATG AGC GGT GAG CTT	897
Gly Ile Ala Arg Ala Tyr Gly Leu Glu Asn Ala Met Ser Gly Glu Leu	
40 45 50	
GTT GAG TTT TCA AAT GGT ATA CTT GGT ATG GCG CAA AAC TTG GAT GCT	945
Val Glu Phe Ser Asn Gly Ile Leu Gly Met Ala Gln Asn Leu Asp Ala	
55 60 65	
ACA GAC GTT GGT ATT ATC GTA CTT GGT GAT TTC CTC TCA ATT CGT GAA	993
Thr Asp Val Gly Ile Ile Val Leu Gly Asp Phe Leu Ser Ile Arg Glu	
70 75 80	
GGT GAC ACT GTT AAA CGT ACA GGT AAA ATC ATG GAA ATC CAA GTT GGT	1041
Gly Asp Thr Val Lys Arg Thr Gly Lys Ile Met Glu Ile Gln Val Gly	
85 90 95 100	
GAA GAA CTC ATC GGA CGT GTT GTA AAC CCA CTT GGA CAA CCC GTT GAT	1089
Glu Glu Leu Ile Gly Arg Val Val Asn Pro Leu Gly Gln Pro Val Asp	
105 110 115	
GGA CTT GGA GAA CTT AAT ACA GGT AAA ACT CGT CCA GTT GAA GCA AAA	1137
Gly Leu Gly Glu Leu Asn Thr Gly Lys Thr Arg Pro Val Glu Ala Lys	
120 125 130	
GCT CCT GGT GTT ATG CAA CGT AAA TCA GTC TCT GAG CCA TTA CAA ACT	1185
Ala Pro Gly Val Met Gln Arg Lys Ser Val Ser Glu Pro Leu Gln Thr	
135 140 145	
GGT CTT AAA GCG ATT GAT GCC CTC GTT CCA ATT GGA CGT GGA CAA CGT	1233
Gly Leu Lys Ala Ile Asp Ala Leu Val Pro Ile Gly Arg Gly Gln Arg	
150 155 160	

GAA	TTA	ATT	ATC	GGA	GAC	CGT	CAA	ACT	GGT	AAA	ACT	TCA	GTC	GCT	ATT	1281
Glu	Leu	Ile	Ile	Gly	Asp	Arg	Gln	Thr	Gly	Lys	Thr	Ser	Val	Ala	Ile	
165					170					175					180	
GAT	GCA	ATC	TTG	AAC	CAA	AAA	GGT	CAA	GAT	ATG	ATT	TGT	ATC	TAT	GTT	1329
Asp	Ala	Ile	Leu	Asn	Gln	Lys	Gly	Gln	Asp	Met	Ile	Cys	Ile	Tyr	Val	
				185					190						195	
GCG	ATT	GGA	CAA	AAA	GAG	TCA	ACA	GTT	CGT	ACA	CAA	GTT	GAA	ACG	CTC	1377
Ala	Ile	Gly	Gln	Lys	Glu	Ser	Thr	Val	Arg	Thr	Gln	Val	Glu	Thr	Leu	
			200					205					210			
CGT	AAA	CTC	GGT	GCG	ATG	GAT	TAT	ACA	ATC	GTC	GTA	ACT	GCG	TCA	GCT	1425
Arg	Lys	Leu	Gly	Ala	Met	Asp	Tyr	Thr	Ile	Val	Val	Thr	Ala	Ser	Ala	
		215					220					225				
TCT	CAA	CCT	TCT	CCA	CTC	CTT	TAC	ATC	GCT	CCT	TAC	GCT	GGA	GCT	GCA	1473
Ser	Gln	Pro	Ser	Pro	Leu	Leu	Tyr	Ile	Ala	Pro	Tyr	Ala	Gly	Ala	Ala	
		230				235					240					
ATG	GGT	GAA	GAA	TTT	ATG	TAT	AAC	GGT	AAA	CAT	GTC	TTG	GTT	GTT	TAT	1521
Met	Gly	Glu	Glu	Phe	Met	Tyr	Asn	Gly	Lys	His	Val	Leu	Val	Val	Tyr	
245					250				255						260	
GAT	GAT	TTA	TCT	AAA	CAA	GCG	GTC	GCT	TAC	CGT	GAA	CTT	TCT	CTC	TTG	1569
Asp	Asp	Leu	Ser	Lys	Gln	Ala	Val	Ala	Tyr	Arg	Glu	Leu	Ser	Leu	Leu	
				265					270					275		
CTC	CGT	CGT	CCA	CCA	GGT	CGT	GAA	GCA	TAC	CCA	GGT	GAC	GTT	TTC	TAC	1617
Leu	Arg	Arg	Pro	Pro	Gly	Arg	Glu	Ala	Tyr	Pro	Gly	Asp	Val	Phe	Tyr	
			280					285					290			
TTG	CAC	TCA	CGT	CTT	TTG	GAA	CGT	GCT	GCT	AAA	TTG	TCT	GAT	GAT	CTT	1665
Leu	His	Ser	Arg	Leu	Leu	Glu	Arg	Ala	Ala	Lys	Leu	Ser	Asp	Asp	Leu	
		295					300					305				
GGT	GGT	GGA	TCA	ATG	ACG	GCT	TTG	CCA	TTC	ATT	GAA	ACA	CAA	GCA	GGT	1713
Gly	Gly	Gly	Ser	Met	Thr	Ala	Leu	Pro	Phe	Ile	Glu	Thr	Gln	Ala	Gly	
		310				315					320					
GAT	ATC	TCA	GCT	TAT	ATT	CCA	ACA	AAC	GTT	ATC	TCT	ATT	ACC	GAC	GGT	1761
Asp	Ile	Ser	Ala	Tyr	Ile	Pro	Thr	Asn	Val	Ile	Ser	Ile	Thr	Asp	Gly	
325					330				335						340	
CAA	ATT	TTC	CTT	GAA	AAT	GAC	TTG	TTC	TAT	TCA	GGT	GTA	CGT	CCT	GCC	1809
Gln	Ile	Phe	Leu	Glu	Asn	Asp	Leu	Phe	Tyr	Ser	Gly	Val	Arg	Pro	Ala	
				345					350					355		
ATT	GAT	GCT	GGT	TCA	TCA	GTA	TCA	CGT	GTT	GGT	GGT	GCC	GCA	CAA	ATC	1857
Ile	Asp	Ala	Gly	Ser	Ser	Val	Ser	Arg	Val	Gly	Gly	Ala	Ala	Gln	Ile	
			360					365					370			
AAA	GCC	ATG	AAG	AAA	GTA	GCT	GGT	ACT	TTG	CGT	CTT	GAC	CTT	GCG	TCG	1905
Lys	Ala	Met	Lys	Lys	Val	Ala	Gly	Thr	Leu	Arg	Leu	Asp	Leu	Ala	Ser	
		375					380					385				
TTC	CGT	GAA	CTT	GAA	GCC	TTT	ACA	CAA	TTT	GGT	TCT	GAC	CTT	GAT	GAA	1953
Phe	Arg	Glu	Leu	Glu	Ala	Phe	Thr	Gln	Phe	Gly	Ser	Asp	Leu	Asp	Glu	
		390					395				400					
GCG	ACT	CAA	GCA	AAA	TTG	AAT	CGT	GGT	CGT	CGT	ACC	GTT	GAA	GTC	TTG	2001
Ala	Thr	Gln	Ala	Lys	Leu	Asn	Arg	Gly	Arg	Arg	Thr	Val	Glu	Val	Leu	
405					410				415						420	

AAA CAA CCA TTG CAC AAA CCA TTG GCT GTT GAA AAA CAA GTT TTG ATT Lys Gln Pro Leu His Lys Pro Leu Ala Val Glu Lys Gln Val Leu Ile 425 430 435	2049
CTC TAT GCA TTG ACT CAT GGT CAT CTT GAT AAT GTT CCA GTT GAT GAT Leu Tyr Ala Leu Thr His Gly His Leu Asp Asn Val Pro Val Asp Asp 440 445 450	2097
GTT CTT GAT TTT GAA ACT AAA ATG TTC GAT TTC TTC GAT GCA AAT TAT Val Leu Asp Phe Glu Thr Lys Met Phe Asp Phe Phe Asp Ala Asn Tyr 455 460 465	2145
GCA GAT CTC TTG AAC GTA ATT ACT GAC ACT AAA GAT TTG CCA GAA GAA Ala Asp Leu Leu Asn Val Ile Thr Asp Thr Lys Asp Leu Pro Glu Glu 470 475 480	2193
GCA AAA CTT GAC GAA GCA ATT AAA GCA TTC AAA AAT ACA ACG AAT TAT Ala Lys Leu Asp Glu Ala Ile Lys Ala Phe Lys Asn Thr Thr Asn Tyr 485 490 495 500	2241
TAATAAGGAG GCTAACTA ATG GGA GCT TCA CTT AAC GAA ATA AAA ACT AAG Met Gly Ala Ser Leu Asn Glu Ile Lys Thr Lys 1 5 10	2292
ATT GCG TCA ACA AAG AAA ACA AGT CAA ATC ACA GGT GCC ATG CAA ATG Ile Ala Ser Thr Lys Lys Thr Ser Gln Ile Thr Gly Ala Met Gln Met 15 20 25	2340
GTT TCT GCT GCT AAA CTT CAA AAA GCA GAA TCT CAC GCT AAA GCT TTT Val Ser Ala Ala Lys Leu Gln Lys Ala Glu Ser His Ala Lys Ala Phe 30 35 40	2388
CAG ACT TAT GCT GAA AAA GTA CGT AAG ATT ACG ACT GAC TTA GTT TCA Gln Thr Tyr Ala Glu Lys Val Arg Lys Ile Thr Thr Asp Leu Val Ser 45 50 55	2436
AGC GAT AAT GAG CCG GCC AAA AAT CCG ATG ATG ATT AAA CGT GAA GTC Ser Asp Asn Glu Pro Ala Lys Asn Pro Met Met Ile Lys Arg Glu Val 60 65 70 75	2484
AAG AAA ACT GGC TAT CTC GTT ATC ACA TCA GAT CGT GGG CTT GTT GGC Lys Lys Thr Gly Tyr Leu Val Ile Thr Ser Asp Arg Gly Leu Val Gly 80 85 90	2532
AGT TAT AAT TCA AAT ATT TTG AAG TCT GTT ATA AGT AAT ATA CGT AAA Ser Tyr Asn Ser Asn Ile Leu Lys Ser Val Ile Ser Asn Ile Arg Lys 95 100 105	2580
CGC CAC ACA AAT GAG AGT GAG TAT ACA ATA CTT GCC CTT GGT GGT ACG Arg His Thr Asn Glu Ser Glu Tyr Thr Ile Leu Ala Leu Gly Gly Thr 110 115 120	2628
GGA GCG GAC TTT TTC AAA GCC CGT AAC GTC AAA GTT TCT TAT GTT CTT Gly Ala Asp Phe Phe Lys Ala Arg Asn Val Lys Val Ser Tyr Val Leu 125 130 135	2676
CGC GGA CTT TCA GAT CAA CCG ACC TTT GAA GAG GTT CGG GCA ATT GTT Arg Gly Leu Ser Asp Gln Pro Thr Phe Glu Glu Val Arg Ala Ile Val 140 145 150 155	2724
ACA GAA GCC GTA GAA GAA TAT CAA GCA GAA GAA TTC GAT GAA CTC TAT Thr Glu Ala Val Glu Glu Tyr Gln Ala Glu Glu Phe Asp Glu Leu Tyr 160 165 170	2772

GTT TGT TAC AAC CAC CAT GTG AAC TCA TTG GTA AGT GAG GCA CGG ATG Val Cys Tyr Asn His His Val Asn Ser Leu Val Ser Glu Ala Arg Met 175 180 185	2820
GAA AAA ATG TTA CCT ATT TCT TTT GAT GAA AAA GGT GAC GAA AAA GCA Glu Lys Met Leu Pro Ile Ser Phe Asp Glu Lys Gly Asp Glu Lys Ala 190 195 200	2868
TCT CTT GTT ACA TTT GAA TTA GAA CCA GAT CGT GAA ACA ATC TTA AAT Ser Leu Val Thr Phe Glu Leu Glu Pro Asp Arg Glu Thr Ile Leu Asn 205 210 215	2916
CAG TTG TTG CCG CAA TAT GCT GAA AGT ATG ATT TAT GGC TCA ATT GTT Gln Leu Leu Pro Gln Tyr Ala Glu Ser Met Ile Tyr Gly Ser Ile Val 220 225 230 235	2964
GAT GCA AAA ACA GCA GAA CAT GCT GCA GGT ATG ACC GCA ATG CGT ACT Asp Ala Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala Met Arg Thr 240 245 250	3012
GCA ACA GAT AAT GCA CAT TCT GTC ATT AAT GAT TTA ACC ATT CAA TAT Ala Thr Asp Asn Ala His Ser Val Ile Asn Asp Leu Thr Ile Gln Tyr 255 260 265	3060
AAC CGT GCT CGT CAA GCT TCA ATT ACG CAA GAA ATT ACG GAA ATT GTT Asn Arg Ala Arg Gln Ala Ser Ile Thr Gln Glu Ile Thr Glu Ile Val 270 275 280	3108
GCG GGT GCT TCA GCG CTA TAATTACTGT CAAACATTAT TCTCAATGTT Ala Gly Ala Ser Ala Leu 285	3156
ACGATTTATC AACTTGAGGA ATAAATGTTC TGTCAGTAAA GGCTTTGAAT TTAAATACG	3216
TTTGTCAGTA AATTTTACT GATTAGCTTA AAAATGAATA GAAATTTCTGT TGTTAGACAG	3276
AAAATAAAAA CAGGAGGAAA AACA TTG AGT TCT GGT AAA ATT ACT CAG GTT Leu Ser Ser Gly Lys Ile Thr Gln Val 1 5	3327
ATC GGT CCC GTC GTT GAC GTG GAA TTT GGT TCT GAT GCC AAA CTG CCT Ile Gly Pro Val Val Asp Val Glu Phe Gly Ser Asp Ala Lys Leu Pro 10 15 20 25	3375
GAG ATT AAC AAT GCC TTG ATT GTC TAC AAA GAT GTC AAT GGT TTA AAA Glu Ile Asn Asn Ala Leu Ile Val Tyr Lys Asp Val Asn Gly Leu Lys 30 35 40	3423
ACA AAA ATT ACT CTT GAA GTT GCT TTG GAA CTT GGT GAT GGT GCA GTT Thr Lys Ile Thr Leu Glu Val Ala Leu Glu Leu Gly Asp Gly Ala Val 45 50 55	3471
CGT ACG ATC GCT ATG GAA TCT ACT GAT GGA TTG ACT CGT GGA CTT GAA Arg Thr Ile Ala Met Glu Ser Thr Asp Gly Leu Thr Arg Gly Leu Glu 60 65 70	3519
GTC CTT GAT ACA GGT AAA GCG GTC AGC GTT CCT GTT GGT GAA TCT ACT Val Leu Asp Thr Gly Lys Ala Val Ser Val Pro Val Gly Glu Ser Thr 75 80 85	3567
CTT GGT CGT GTT TTT AAT GTC CTT GGT GAC GTT ATT GAT GGT GGA GAA Leu Gly Arg Val Phe Asn Val Leu Gly Asp Val Ile Asp Gly Gly Glu 90 95 100 105	3615

GAT	TTC	CCT	GCT	GAT	GCA	GAA	CGT	AAT	CCT	ATC	CAC	AAG	AAA	GCT	CCA	3663
Asp	Phe	Pro	Ala	Asp	Ala	Glu	Arg	Asn	Pro	Ile	His	Lys	Lys	Ala	Pro	
				110					115					120		
ACT	TTT	GAC	GAA	TTG	TCA	ACT	GCA	AAT	GAA	GTT	CTT	GTA	ACA	GGG	ATT	3711
Thr	Phe	Asp	Glu	Leu	Ser	Thr	Ala	Asn	Glu	Val	Leu	Val	Thr	Gly	Ile	
			125					130					135			
AAA	GTT	GTC	GAT	TTA	CTT	GCC	CCT	TAT	CTT	AAA	GGT	GGG	AAA	GTC	GGA	3759
Lys	Val	Val	Asp	Leu	Leu	Ala	Pro	Tyr	Leu	Lys	Gly	Gly	Lys	Val	Gly	
		140					145					150				
CTC	TTC	GGT	GGT	GCC	GGT	GTT	GGT	AAA	ACC	GTC	CTT	ATC	CAA	GAA	TTG	3807
Leu	Phe	Gly	Gly	Ala	Gly	Val	Gly	Lys	Thr	Val	Leu	Ile	Gln	Glu	Leu	
		155				160					165					
ATT	CAC	AAT	ATT	GCC	CAA	GAA	CAC	GGT	GGT	ATT	TCT	GTA	TTT	ACA	GGT	3855
Ile	His	Asn	Ile	Ala	Gln	Glu	His	Gly	Gly	Ile	Ser	Val	Phe	Thr	Gly	
				175				180							185	
GTT	GGC	GAT	CGT	ACT	CGT	GAC	GGG	AAT	GAC	CTT	TAC	TGG	GAA	ATG	AAA	3903
Val	Gly	Asp	Arg	Thr	Arg	Asp	Gly	Asn	Asp	Leu	Tyr	Trp	Glu	Met	Lys	
				190				195						200		
GAA	TCA	GGC	GTT	ATT	GAA	AAA	ACA	GCC	ATG	GTC	TTT	GGT	CAA	ATG	AAT	3951
Glu	Ser	Gly	Val	Ile	Glu	Lys	Thr	Ala	Met	Val	Phe	Gly	Gln	Met	Asn	
			205					210					215			
GAA	CCA	CCT	GGA	GCA	CGT	ATG	CGT	GTT	GCC	CTT	ACT	GGT	TTA	ACA	ATT	3999
Glu	Pro	Pro	Gly	Ala	Arg	Met	Arg	Val	Ala	Leu	Thr	Gly	Leu	Thr	Ile	
		220					225					230				
GCG	GAA	TAT	TTC	CGT	GAT	GTT	CAA	GGA	CAA	GAC	GTA	TTG	CTT	TTC	ATC	4047
Ala	Glu	Tyr	Phe	Arg	Asp	Val	Gln	Gly	Gln	Asp	Val	Leu	Leu	Phe	Ile	
		235				240					245					
GAT	AAC	ATC	TTC	CGT	TTC	ACT	CAA	GCT	GGT	TCA	GAA	GTT	TCT	GCC	CTT	4095
Asp	Asn	Ile	Phe	Arg	Phe	Thr	Gln	Ala	Gly	Ser	Glu	Val	Ser	Ala	Leu	
		250				255				260					265	
TGG	GGA	CGT	ATG	CCT	TCT	GCC	GTT	GGT	TAC	CAA	CCA	ACT	CTT	GCA	ACT	4143
Trp	Gly	Arg	Met	Pro	Ser	Ala	Val	Gly	Tyr	Gln	Pro	Thr	Leu	Ala	Thr	
				270					275					280		
GAA	ATG	GTT	CAA	TTA	CAG	GAA	CGT	ATC	ACT	TCT	ACT	AAG	AAG	GGT	TCT	4191
Glu	Met	Val	Gln	Leu	Gln	Glu	Arg	Ile	Thr	Ser	Thr	Lys	Lys	Gly	Ser	
			285					290					295			
GTT	ACA	TCT	ATC	CCA	GCG	ATT	TAT	GTC	CCT	GCC	GAT	GAC	TAT	ACT	GAC	4239
Val	Thr	Ser	Ile	Pro	Ala	Ile	Tyr	Val	Pro	Ala	Asp	Asp	Tyr	Thr	Asp	
			300				305					310				
CCA	GCG	CCA	GCT	ACA	GCC	TTC	GCT	CAC	TTG	GAC	GCA	ACA	ACT	AAC	TTG	4287
Pro	Ala	Pro	Ala	Thr	Ala	Phe	Ala	His	Leu	Asp	Ala	Thr	Thr	Asn	Leu	
		315				320					325					
GAA	CGT	CGT	TTG	ACA	CAA	ATG	GGT	ATC	TAT	CCA	GCC	GTT	GAC	CCA	CTT	4335
Glu	Arg	Arg	Leu	Thr	Gln	Met	Gly	Ile	Tyr	Pro	Ala	Val	Asp	Pro	Leu	
			330			335				340					345	
GCT	TCA	TCA	TCA	CGT	GCG	CTT	ACA	CCT	GAA	ATT	GTT	GGT	GAA	GAA	CAC	4383
Ala	Ser	Ser	Ser	Arg	Ala	Leu	Thr	Pro	Glu	Ile	Val	Gly	Glu	Glu	His	
				350					355					360		

TAT GAA GTT GCA ATG GAA GTT CAA CGT GTC CTT CAA CGC TAC AAA GAA 4431
 Tyr Glu Val Ala Met Glu Val Gln Arg Val Leu Gln Arg Tyr Lys Glu
 365 370 375
 TTG CAA GAT ATC ATT GCC ATT CTT GGT ATG GAT GAA TTG TCA GAT GAT 4479
 Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser Asp Asp
 380 385 390
 GAA AAA ATT CTC GTT GGA CGT GCA CGT CGT ATC CAA TTC TTC CTT TCA 4527
 Glu Lys Ile Leu Val Gly Arg Ala Arg Arg Ile Gln Phe Phe Leu Ser
 395 400 405
 CAA AAC TTC CAC GTT GCT GAA CAG TTT ACT GGT CAA CCT GGT TCA TAT 4575
 Gln Asn Phe His Val Ala Glu Gln Phe Thr Gly Gln Pro Gly Ser Tyr
 410 415 420 425
 GTA CCA ATT GAC AAA ACA GTT CAT GAC TTC AAG GAA ATT TTG GAA GGT 4623
 Val Pro Ile Asp Lys Thr Val His Asp Phe Lys Glu Ile Leu Glu Gly
 430 435 440
 AAA TAT GAC GAA GTC CCT GAA GAT GCT TTC CGT GGA GTA GGT CCA ATT 4671
 Lys Tyr Asp Glu Val Pro Glu Asp Ala Phe Arg Gly Val Gly Pro Ile
 445 450 455
 GAA GAC GTA CTT GCA AAA GCA AAA TCA ATG GGT TAT TAATTCGATT -4717
 Glu Asp Val Leu Ala Lys Ala Lys Ser Met Gly Tyr
 460 465
 TCTTATGAAA TGACAAAGTG AAAATACATT ATTGAATCGC AAAATTTACT GACAATAATT -4777
 CTGTCGTAAG TGCTCACTTT TAAGTTGTTC CGATCGTT 4815

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Thr Lys Val Asn Ser Gln Lys Tyr Ser Lys Ala Leu Leu Glu Val
 1 5 10 15
 Ala Arg Glu Lys Gly Gln Leu Glu Ala Ile Leu Thr Glu Val Ser Glu
 20 25 30
 Met Ile Gln Leu Phe Lys Glu Asn Asn Leu Gly Ala Phe Leu Ala Asn
 35 40 45
 Glu Val Tyr Ser Phe Ser Ala Lys Ser Glu Leu Ile Asp Thr Leu Leu
 50 55 60
 Gln Thr Ser Ser Glu Val Met Ser Asn Phe Leu Asn Thr Ile Arg Ser
 65 70 75 80
 Asn Gly Arg Leu Ala Asp Leu Gly Glu Ile Leu Glu Glu Thr Lys Asn
 85 90 95
 Ala Ala Asp Asp Met Phe Lys Ile Ala Asp Val Glu Val Val Ser Ser
 100 105 110

Ile Ala Leu Ser Glu Ala Gln Ile Glu Lys Phe Lys Ala Met Ala Lys
 115 120 125

Ser Lys Phe Asp Leu Asn Glu Val Thr Val Ile Asn Thr Val Asn Glu
 130 135 140

Lys Ile Leu Gly Gly Phe Ile Val Asn Ser Arg Gly Lys Ile Ile Asp
 145 150 155 160

Ala Ser Leu Lys Thr Gln Leu Ala Lys Ile Ala Ala Glu Ile Leu
 165 170 175

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 500 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Leu Ala Ile Lys Ala Asn Glu Ile Ser Ser Leu Ile Lys Lys Gln Ile
 1 5 10 15

Glu Asn Phe Thr Pro Asp Phe Glu Val Ala Glu Thr Gly Val Val Thr
 20 25 30

Tyr Val Gly Asp Gly Ile Ala Arg Ala Tyr Gly Leu Glu Asn Ala Met
 35 40 45

Ser Gly Glu Leu Val Glu Phe Ser Asn Gly Ile Leu Gly Met Ala Gln
 50 55 60

Asn Leu Asp Ala Thr Asp Val Gly Ile Ile Val Leu Gly Asp Phe Leu
 65 70 75 80

Ser Ile Arg Glu Gly Asp Thr Val Lys Arg Thr Gly Lys Ile Met Glu
 85 90 95

Ile Gln Val Gly Glu Glu Leu Ile Gly Arg Val Val Asn Pro Leu Gly
 100 105 110

Gln Pro Val Asp Gly Leu Gly Glu Leu Asn Thr Gly Lys Thr Arg Pro
 115 120 125

Val Glu Ala Lys Ala Pro Gly Val Met Gln Arg Lys Ser Val Ser Glu
 130 135 140

Pro Leu Gln Thr Gly Leu Lys Ala Ile Asp Ala Leu Val Pro Ile Gly
 145 150 155 160

Arg Gly Gln Arg Glu Leu Ile Ile Gly Asp Arg Gln Thr Gly Lys Thr
 165 170 175

Ser Val Ala Ile Asp Ala Ile Leu Asn Gln Lys Gly Gln Asp Met Ile
 180 185 190

Cys Ile Tyr Val Ala Ile Gly Gln Lys Glu Ser Thr Val Arg Thr Gln
 195 200 205

Val Glu Thr Leu Arg Lys Leu Gly Ala Met Asp Tyr Thr Ile Val Val
 210 215 220
 Thr Ala Ser Ala Ser Gln Pro Ser Pro Leu Leu Tyr Ile Ala Pro Tyr
 225 230 235 240
 Ala Gly Ala Ala Met Gly Glu Glu Phe Met Tyr Asn Gly Lys His Val
 245 250 255
 Leu Val Val Tyr Asp Asp Leu Ser Lys Gln Ala Val Ala Tyr Arg Glu
 260 265 270
 Leu Ser Leu Leu Leu Arg Arg Pro Pro Gly Arg Glu Ala Tyr Pro Gly
 275 280 285
 Asp Val Phe Tyr Leu His Ser Arg Leu Leu Glu Arg Ala Ala Lys Leu
 290 295 300
 Ser Asp Asp Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Phe Ile Glu
 305 310 315 320
 Thr Gln Ala Gly Asp Ile Ser Ala Tyr Ile Pro Thr Asn Val Ile Ser
 325 330 335
 Ile Thr Asp Gly Gln Ile Phe Leu Glu Asn Asp Leu Phe Tyr Ser Gly
 340 345 350
 Val Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly
 355 360 365
 Ala Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu
 370 375 380
 Asp Leu Ala Ser Phe Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser
 385 390 395 400
 Asp Leu Asp Glu Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr
 405 410 415
 Val Glu Val Leu Lys Gln Pro Leu His Lys Pro Leu Ala Val Glu Lys
 420 425 430
 Gln Val Leu Ile Leu Tyr Ala Leu Thr His Gly His Leu Asp Asn Val
 435 440 445
 Pro Val Asp Asp Val Leu Asp Phe Glu Thr Lys Met Phe Asp Phe Phe
 450 455 460
 Asp Ala Asn Tyr Ala Asp Leu Leu Asn Val Ile Thr Asp Thr Lys Asp
 465 470 475 480
 Leu Pro Glu Glu Ala Lys Leu Asp Glu Ala Ile Lys Ala Phe Lys Asn
 485 490 495
 Thr Thr Asn Tyr
 500

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 289 amino acids
 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Met Gly Ala Ser Leu Asn Glu Ile Lys Thr Lys Ile Ala Ser Thr Lys
 1             5             10             15

Lys Thr Ser Gln Ile Thr Gly Ala Met Gln Met Val Ser Ala Ala Lys
          20             25             30

Leu Gln Lys Ala Glu Ser His Ala Lys Ala Phe Gln Thr Tyr Ala Glu
          35             40             45

Lys Val Arg Lys Ile Thr Thr Asp Leu Val Ser Ser Asp Asn Glu Pro
          50             55             60

Ala Lys Asn Pro Met Met Ile Lys Arg Glu Val Lys Lys Thr Gly Tyr
          65             70             75             80

Leu Val Ile Thr Ser Asp Arg Gly Leu Val Gly Ser Tyr Asn Ser Asn
          85             90             95

Ile Leu Lys Ser Val Ile Ser Asn Ile Arg Lys Arg His Thr Asn Glu
          100            105            110

Ser Glu Tyr Thr Ile Leu Ala Leu Gly Gly Thr Gly Ala Asp Phe Phe
          115            120            125

Lys Ala Arg Asn Val Lys Val Ser Tyr Val Leu Arg Gly Leu Ser Asp
          130            135            140

Gln Pro Thr Phe Glu Glu Val Arg Ala Ile Val Thr Glu Ala Val Glu
          145            150            155            160

Glu Tyr Gln Ala Glu Glu Phe Asp Glu Leu Tyr Val Cys Tyr Asn His
          165            170            175

His Val Asn Ser Leu Val Ser Glu Ala Arg Met Glu Lys Met Leu Pro
          180            185            190

Ile Ser Phe Asp Glu Lys Gly Asp Glu Lys Ala Ser Leu Val Thr Phe
          195            200            205

Glu Leu Glu Pro Asp Arg Glu Thr Ile Leu Asn Gln Leu Leu Pro Gln
          210            215            220

Tyr Ala Glu Ser Met Ile Tyr Gly Ser Ile Val Asp Ala Lys Thr Ala
          225            230            235            240

Glu His Ala Ala Gly Met Thr Ala Met Arg Thr Ala Thr Asp Asn Ala
          245            250            255

His Ser Val Ile Asn Asp Leu Thr Ile Gln Tyr Asn Arg Ala Arg Gln
          260            265            270

Ala Ser Ile Thr Gln Glu Ile Thr Glu Ile Val Ala Gly Ala Ser Ala
          275            280            285

Leu

```


(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 469 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```

Leu Ser Ser Gly Lys Ile Thr Gln Val Ile Gly Pro Val Val Asp Val
 1           5           10           15
Glu Phe Gly Ser Asp Ala Lys Leu Pro Glu Ile Asn Asn Ala Leu Ile
          20           25           30
Val Tyr Lys Asp Val Asn Gly Leu Lys Thr Lys Ile Thr Leu Glu Val
          35           40           45
Ala Leu Glu Leu Gly Asp Gly Ala Val Arg Thr Ile Ala Met Glu Ser
          50           55           60
Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Lys Ala
          65           70           75           80
Val Ser Val Pro Val Gly Glu Ser Thr Leu Gly Arg Val Phe Asn Val
          85           90           95
Leu Gly Asp Val Ile Asp Gly Gly Glu Asp Phe Pro Ala Asp Ala Glu
          100          105          110
Arg Asn Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr
          115          120          125
Ala Asn Glu Val Leu Val Thr Gly Ile Lys Val Val Asp Leu Leu Ala
          130          135          140
Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val
          145          150          155          160
Gly Lys Thr Val Leu Ile Gln Glu Leu Ile His Asn Ile Ala Gln Glu
          165          170          175
His Gly Gly Ile Ser Val Phe Thr Gly Val Gly Asp Arg Thr Arg Asp
          180          185          190
Gly Asn Asp Leu Tyr Trp Glu Met Lys Glu Ser Gly Val Ile Glu Lys
          195          200          205
Thr Ala Met Val Phe Gly Gln Met Asn Glu Pro Pro Gly Ala Arg Met
          210          215          220
Arg Val Ala Leu Thr Gly Leu Thr Ile Ala Glu Tyr Phe Arg Asp Val
          225          230          235          240
Gln Gly Gln Asp Val Leu Leu Phe Ile Asp Asn Ile Phe Arg Phe Thr
          245          250          255
Gln Ala Gly Ser Glu Val Ser Ala Leu Trp Gly Arg Met Pro Ser Ala
          260          265          270
Val Gly Tyr Gln Pro Thr Leu Ala Thr Glu Met Val Gln Leu Gln Glu
          275          280          285

```

Arg Ile Thr Ser Thr Lys Lys Gly Ser Val Thr Ser Ile Pro Ala Ile
 290 300
 Tyr Val Pro Ala Asp Asp Tyr Thr Asp Pro Ala Pro Ala Thr Ala Phe
 305 310 315 320
 Ala His Leu Asp Ala Thr Thr Asn Leu Glu Arg Arg Leu Thr Gln Met
 325 330 335
 Gly Ile Tyr Pro Ala Val Asp Pro Leu Ala Ser Ser Ser Arg Ala Leu
 340 345 350
 Thr Pro Glu Ile Val Gly Glu Glu His Tyr Glu Val Ala Met Glu Val
 355 360 365
 Gln Arg Val Leu Gln Arg Tyr Lys Glu Leu Gln Asp Ile Ile Ala Ile
 370 375 380
 Leu Gly Met Asp Glu Leu Ser Asp Asp Glu Lys Ile Leu Val Gly Arg
 385 390 395 400
 Ala Arg Arg Ile Gln Phe Phe Leu Ser Gln Asn Phe His Val Ala Glu
 405 410 415
 Gln Phe Thr Gly Gln Pro Gly Ser Tyr Val Pro Ile Asp Lys Thr Val
 420 425 430
 His Asp Phe Lys Glu Ile Leu Glu Gly Lys Tyr Asp Glu Val Pro Glu
 435 440 445
 Asp Ala Phe Arg Gly Val Gly Pro Ile Glu Asp Val Leu Ala Lys Ala
 450 455 460
 Lys Ser Met Gly Tyr
 465

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2207 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Lactococcus lactis* subsp. *lactis*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 4..633
- (D) OTHER INFORMATION: /partial
 /codon_start= 4
 /product= "ATPase subunit, partial sequence"
 /gene= "atpA"
 /standard_name= "alpha subunit of the F1 portion
 of the FO₁ ATPase"
 /label= alpha-subunit

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION:652..1518
 (D) OTHER INFORMATION:/codon_start= 652
 /product= "ATPase subunit"
 /gene= "atpG"
 /standard_name= "gamma subunit of the F1 portion
 of the F0F1 ATPase"
 /label= gamma-subunit

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION:1654..2205
 (D) OTHER INFORMATION:/partial
 /codon_start= 1654
 /product= "ATPase subunit, partial sequence"
 /gene= "atpD"
 /standard_name= "beta subunit of the F1 portion of
 the F0F1 ATPase"
 /label= beta-subunit

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TGA	TTC	TAC	TTA	CAT	TCA	CGT	CTT	TTG	GAA	CGT	GCT	GCC	AAA	TTA	TCT	48
	Phe	Tyr	Leu	His	Ser	Arg	Leu	Leu	Glu	Arg	Ala	Ala	Lys	Leu	Ser	
	470					475					480					
GAC	TAT	CTT	GGT	GGT	GGT	TCA	ATG	ACT	GCA	CTG	CCA	TTC	ATT	GAA	ACA	96
Asp	Tyr	Leu	Gly	Gly	Gly	Ser	Met	Thr	Ala	Leu	Pro	Phe	Ile	Glu	Thr	
485					490					495					500	
CAA	GCC	GGA	GAT	ATC	TCA	GCT	TAT	ATT	GCA	ACA	AAC	GTT	ATC	TCT	ATT	144
Gln	Ala	Gly	Asp	Ile	Ser	Ala	Tyr	Ile	Ala	Thr	Asn	Val	Ile	Ser	Ile	
				505					510					515		
ACT	GAC	GGT	CAA	ATT	TTC	CTT	GAA	AAT	GAC	TTA	TTC	TAT	TCA	GGT	GTA	192
Thr	Asp	Gly	Gln	Ile	Phe	Leu	Glu	Asn	Asp	Leu	Phe	Tyr	Ser	Gly	Val	
			520					525					530			
CGT	CCT	GCC	ATC	GAT	GCT	GGT	TCT	TCA	GTT	TCT	CGG	GTT	GGT	GGT	GCT	240
Arg	Pro	Ala	Ile	Asp	Ala	Gly	Ser	Ser	Val	Ser	Arg	Val	Gly	Gly	Ala	
		535				540					545					
GCA	CAG	ATC	AAA	GCC	ATG	AAG	AAA	GTT	GCT	GGT	ACT	TTG	CGT	CTT	GAC	288
Ala	Gln	Ile	Lys	Ala	Met	Lys	Lys	Val	Ala	Gly	Thr	Leu	Arg	Leu	Asp	
		550				555					560					
CTT	GCG	TCA	TTC	CGT	GAA	CTT	GAA	GCC	TTT	ACT	CAA	TTT	GGT	TCT	GAT	336
Leu	Ala	Ser	Phe	Arg	Glu	Leu	Glu	Ala	Phe	Thr	Gln	Phe	Gly	Ser	Asp	
565					570					575					580	
CTT	GAT	GAA	GCG	ACT	CAA	GCA	AAA	TTG	AAT	CGT	GGT	CGT	CGT	ACC	GTT	384
Leu	Asp	Glu	Ala	Thr	Gln	Ala	Lys	Leu	Asn	Arg	Gly	Arg	Arg	Thr	Val	
				585				590						595		
GAA	GTT	TTG	AAG	CAA	CCA	TTG	CAC	AAA	CCA	TTG	GCT	GTT	GAA	AAA	CAA	432
Glu	Val	Leu	Lys	Gln	Pro	Leu	His	Lys	Pro	Leu	Ala	Val	Glu	Lys	Gln	
			600					605					610			
GTT	TTA	ATT	CTT	TAT	GCA	TTG	ACT	CAT	GGT	CAC	TTG	GAT	GAT	GTT	CCA	480
Val	Leu	Ile	Leu	Tyr	Ala	Leu	Thr	His	Gly	His	Leu	Asp	Asp	Val	Pro	
			615				620						625			

GTT GAT GAC GTC CTT GAT TTT GAA ACA AAC AAT GTC CGA TTC TTC GAT Val Asp Asp Val Leu Asp Phe Glu Thr Asn Asn Val Arg Phe Phe Asp 630 635 640	528
GCA AAT TAT GCA AAA CTC TTG AAC GTG ATT ACT GAA ACT AAA GAT TGC Ala Asn Tyr Ala Lys Leu Leu Asn Val Ile Thr Glu Thr Lys Asp Cys 645 650 655 660	576
CAG AAG AAG CAA AAC TCG ACG AAG CAA TTA AAG CAT TCT AAA ATA CAA Gln Lys Lys Gln Asn Ser Thr Lys Gln Leu Lys His Ser Lys Ile Gln 665 670 675	624
CGA ATT ATT AATAAGGAGG CTAATCTA ATG GGA GCT TCA CTT AAT GAA ATA Arg Ile Ile Met Gly Ala Ser Leu Asn Glu Ile 1 5	675
AAA ACT AAG ATT GCC TCA ACG AAG AAA ACA AGT CAA ATA ACT GGA GCC Lys Thr Lys Ile Ala Ser Thr Lys Lys Thr Ser Gln Ile Thr Gly Ala 10 15 20	723
ATG CAA ATG GTT TCC GCT GCG AAA CTT CAA AAA GCT GAA TCT CAT GCC Met Gln Met Val Ser Ala Ala Lys Leu Gln Lys Ala Glu Ser His Ala 25 30 35 40	771
AAA GCA TTT CAA ATT TAT GCT GAA AAA GTT CGT AAA ATT ACA ACT GAT Lys Ala Phe Gln Ile Tyr Ala Glu Lys Val Arg Lys Ile Thr Thr Asp 45 50 55	819
TTA GTT TCC TCT GAC AAA GAG CCA GCT AAG AAT CCA ATG ATG ATA GGA Leu Val Ser Ser Asp Lys Glu Pro Ala Lys Asn Pro Met Met Ile Gly 60 65 70	867
AGA GAA GTC AAA AAA ACT GGC TAT CTT GTA ATT ACT TCG GAT CGT GGA Arg Glu Val Lys Lys Thr Gly Tyr Leu Val Ile Thr Ser Asp Arg Gly 75 80 85	915
CTT GTC GGT GGC TAT AAT TCA TAT ATT TTG AAA TCT GTC ATG AAT ACT Leu Val Gly Gly Tyr Asn Ser Tyr Ile Leu Lys Ser Val Met Asn Thr 90 95 100	963
ATC CGT AAA CGT CCT GCT AAT GAA AGT GAA TAT ACT ATT CTT GCA CTT Ile Arg Lys Arg Pro Ala Asn Glu Ser Glu Tyr Thr Ile Leu Ala Leu 105 110 115 120	1011
GGC GGT ACT GGA GCA GAT TTC TTC GGA GCA AGC AAT GTT AAA AGT TTC Gly Gly Thr Gly Ala Asp Phe Phe Gly Ala Ser Asn Val Lys Ser Phe 125 130 135	1059
TTA GTC CTT TGT GGT TTT TCA GAC CAA CCA AAT TTT GAA GAA GTT AGA Leu Val Leu Cys Gly Phe Ser Asp Gln Pro Asn Phe Glu Glu Val Arg 140 145 150	1107
GCG ATT GTT ACA GAA GCG GTA ACT GAA TAT CAA GCA GAA GAA TTT GAT Ala Ile Val Thr Glu Ala Val Thr Glu Tyr Gln Ala Glu Glu Phe Asp 155 160 165	1155
GAA CTT TAT GTT TGC TAT AAT CAC CAT GTG AAC TCA TTG GTA AGT GAA Glu Leu Tyr Val Cys Tyr Asn His His Val Asn Ser Leu Val Ser Glu 170 175 180	1203
GCA AGT ATG GAA AAA ATG TTG CCT ATT TTT TTT GAA GCA TCA GGT CAA Ala Ser Met Glu Lys Met Leu Pro Ile Phe Phe Glu Ala Ser Gly Gln 185 190 195 200	1251

CAA AAA CCA TTT TTT GAA ACA TTT GAA TTA GAA CCA GAT TGT GAA ACA Gln Lys Pro Phe Phe Glu Thr Phe Glu Leu Glu Pro Asp Cys Glu Thr 205 210 215	1299
ATT TTA AAC CAA TTG TTG CCA CCA TAC GCT GAA AGT ATG ATT TAT GGT Ile Leu Asn Gln Leu Leu Pro Pro Tyr Ala Glu Ser Met Ile Tyr Gly 220 225 230	1347
TCA ATC GTT GAT GCT AAG ACA GCA GAA CAT GCT GCA GGT ATG ACA GCA Ser Ile Val Asp Ala Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala 235 240 245	1395
ATG CGT ACT GCA ACT GAT AAT GCT CAC TCT GTT ATC AAT GAT TTG ACT Met Arg Thr Ala Thr Asp Asn Ala His Ser Val Ile Asn Asp Leu Thr 250 255 260	1443
ATT CAA TAC AAC CGT GCT CGT CAA GCA TCG ATT ACG CAA GAA ATT ACG Ile Gln Tyr Asn Arg Ala Arg Gln Ala Ser Ile Thr Gln Glu Ile Thr 265 270 275 280	1491
GAA ATC GTT GCA GGA GCC TCA GCG CTT TAATTTACTG ATAGGAATTC Glu Ile Val Ala Gly Ala Ser Ala Leu 285	1538
TGTCAGTGAT GGCTTTGAAT CTTAATTGTT TTTGTCAGTA AAATTTTAC TGACAAACAT	1598
AAAAATGAAT AGAAATTCTG TTCFTTGACA GAAAATAAAA ACAGGAGGAA AAACA TTG Leu 1	1656
AGT TCT GGT AAA ATT ACT CAG ATT ATC GGT CCC GTC GTT GAC GTG GAA Ser Ser Gly Lys Ile Thr Gln Ile Ile Gly Pro Val Val Asp Val Glu 5 10 15	1704
TTT GGT TCT GAT GCC AAA TTG CCT GAG ATT AAC AAT GCC TTG ATT GTC Phe Gly Ser Asp Ala Lys Leu Pro Glu Ile Asn Asn Ala Leu Ile Val 20 25 30	1752
TAC AAA GAT GTC AAT GGC CTA AAA ACA AAA ATT ACT CTT GAA GTT GCT Tyr Lys Asp Val Asn Gly Leu Lys Thr Lys Ile Thr Leu Glu Val Ala 35 40 45	1800
TTG GAA CTT GGT GAT GGT GCA GTT CGT ACA ATC GCT ATG GAA TCT ACT Leu Glu Leu Gly Asp Gly Ala Val Arg Thr Ile Ala Met Glu Ser Thr 50 55 60 65	1848
GAT GGC TTG ACT CGT GGA CTT GAA GTC CTT GAT ACA GGT AAA GCA GTC Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Lys Ala Val 70 75 80	1896
AGC GTT CCT GTT GGG GAA GCC ACT CTT GGT CGT GTT TTT AAC GTC CTT Ser Val Pro Val Gly Glu Ala Thr Leu Gly Arg Val Phe Asn Val Leu 85 90 95	1944
GGT GAT GTT ATT GAC GGT GGG GAA GAA TTT GCT GCT GAT GCA GAA CGT Gly Asp Val Ile Asp Gly Gly Glu Glu Phe Ala Ala Asp Ala Glu Arg 100 105 110	1992
AAT CCT ATC CAT AAA AAA GCT CCA ACA TTT GAC GAA TTG TCA ACT GCA Asn Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr Ala 115 120 125	2040

AAC GAA GTT CTC GTA ACT GGG ATT AAA GTT GTC GAT TTG CTT GCA CCT	2088
Asn Glu Val Leu Val Thr Gly Ile Lys Val Val Asp Leu Leu Ala Pro	
130 135 140 145	
TAC CTT AAA GGT GGT AAA GTT GGA CTT TTC GGT GGT GCC GGA GTT GGT	2136
Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val Gly	
150 155 160	
AAA GCC GTC CTT ATT CAA GAA TTG AAA CAC AAC ATC GCC CAA GAA CAC	2184
Lys Ala Val Leu Ile Gln Glu Leu Lys His Asn Ile Ala Gln Glu His	
165 170 175	
GGA GGT ATT TCT GTG TTT ACC GG	2207
Gly Gly Ile Ser Val Phe Thr	
180	

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 210 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Phe Tyr Leu His Ser Arg Leu Leu Glu Arg Ala Ala Lys Leu Ser Asp	
1 5 10 15	
Tyr Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Phe Ile Glu Thr Gln	
20 25 30	
Ala Gly Asp Ile Ser Ala Tyr Ile Ala Thr Asn Val Ile Ser Ile Thr	
35 40 45	
Asp Gly Gln Ile Phe Leu Glu Asn Asp Leu Phe Tyr Ser Gly Val Arg	
50 55 60	
Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly Ala Ala	
65 70 75 80	
Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu Asp Leu	
85 90 95	
Ala Ser Phe Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser Asp Leu	
100 105 110	
Asp Glu Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr Val Glu	
115 120 125	
Val Leu Lys Gln Pro Leu His Lys Pro Leu Ala Val Glu Lys Gln Val	
130 135 140	
Leu Ile Leu Tyr Ala Leu Thr His Gly His Leu Asp Asp Val Pro Val	
145 150 155 160	
Asp Asp Val Leu Asp Phe Glu Thr Asn Asn Val Arg Phe Phe Asp Ala	
165 170 175	
Asn Tyr Ala Lys Leu Leu Asn Val Ile Thr Glu Thr Lys Asp Cys Gln	
180 185 190	

Lys Lys Gln Asn Ser Thr Lys Gln Leu Lys His Ser Lys Ile Gln Arg
 195 200 205

Ile Ile
 210

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 289 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Gly Ala Ser Leu Asn Glu Ile Lys Thr Lys Ile Ala Ser Thr Lys
 1 5 10 15

Lys Thr Ser Gln Ile Thr Gly Ala Met Gln Met Val Ser Ala Ala Lys
 20 25 30

Leu Gln Lys Ala Glu Ser His Ala Lys Ala Phe Gln Ile Tyr Ala Glu
 35 40 45

Lys Val Arg Lys Ile Thr Thr Asp Leu Val Ser Ser Asp Lys Glu Pro
 50 55 60

Ala Lys Asn Pro Met Met Ile Gly Arg Glu Val Lys Lys Thr Gly Tyr
 65 70 75 80

Leu Val Ile Thr Ser Asp Arg Gly Leu Val Gly Gly Tyr Asn Ser Tyr
 85 90 95

Ile Leu Lys Ser Val Met Asn Thr Ile Arg Lys Arg Pro Ala Asn Glu
 100 105 110

Ser Glu Tyr Thr Ile Leu Ala Leu Gly Gly Thr Gly Ala Asp Phe Phe
 115 120 125

Gly Ala Ser Asn Val Lys Ser Phe Leu Val Leu Cys Gly Phe Ser Asp
 130 135 140

Gln Pro Asn Phe Glu Glu Val Arg Ala Ile Val Thr Glu Ala Val Thr
 145 150 155 160

Glu Tyr Gln Ala Glu Glu Phe Asp Glu Leu Tyr Val Cys Tyr Asn His
 165 170 175

His Val Asn Ser Leu Val Ser Glu Ala Ser Met Glu Lys Met Leu Pro
 180 185 190

Ile Phe Phe Glu Ala Ser Gly Gln Gln Lys Pro Phe Phe Glu Thr Phe
 195 200 205

Glu Leu Glu Pro Asp Cys Glu Thr Ile Leu Asn Gln Leu Leu Pro Pro
 210 215 220

Tyr Ala Glu Ser Met Ile Tyr Gly Ser Ile Val Asp Ala Lys Thr Ala
 225 230 235 240

BNSDOCID: <WO__9810089A1_I_>

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Streptococcus thermophilus
(B) STRAIN: ST3

(ix) FEATURE:

```
(A) NAME/KEY: CDS
(B) LOCATION:2..637
(D) OTHER INFORMATION:/partial
    /codon_start= 2
    /product= "ATPase subunit, partial sequence"
    /gene= "atpA"
    /standard_name= "alpha subunit of the F1 portion
of the F0F1 ATPase"
    /label= alpha-subunit
```

(ix) FEATURE:

```
(A) NAME/KEY: CDS
(B) LOCATION: 659..1537
(D) OTHER INFORMATION: /codon_start= 659
    /product= "ATPase subunit"
    /gene= "atpG"
    /standard_name= "gamma subunit of the F1 portion
    of the F0F1 ATPase"
    /label= gamma-subunit
```

(ix) FEATURE:

```
(A) NAME/KEY: CDS
(B) LOCATION:1616..2161
(D) OTHER INFORMATION:/partial
    /codon_start= 1616
    /product= "ATPase subunit, partial sequence"
    /gene= "atpD"
    /standard_name= "beta subunit of the F1 portion of
the F0F1 ATPase"
    /label= beta-subunit
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

T	GAT	TCT	CAT	CTC	CAC	TCA	CGT	CTT	TTG	GAA	CGT	TCA	GCT	AAG	CTT	46
	Asp	Ser	His	Leu	His	Ser	Arg	Leu	Leu	Glu	Arg	Ser	Ala	Lys	Leu	
	185					190					195					
TCA	GAT	GAT	CTT	GGT	GGT	GGT	TCA	ATG	ACT	GCC	TTG	CCA	ATC	ATC	CAA	94
Ser	Asp	Asp	Leu	Gly	Gly	Gly	Ser	Met	Thr	Ala	Leu	Pro	Ile	Ile	Gln	
200					205					210					215	
ACA	CAA	GCA	GGA	GAT	ATC	TCA	GCT	TAT	ATC	GCG	ACA	AAC	GTT	ATT	TCT	142
Thr	Gln	Ala	Gly	Asp	Ile	Ser	Ala	Tyr	Ile	Ala	Thr	Asn	Val	Ile	Ser	
				220					225					230		

ATC ACA GAT GGA CAA ATC TTC TTG CAA GAA AAT CTT TTC AAC TCA GGT Ile Thr Asp Gly Gln Ile Phe Leu Gln Glu Asn Leu Phe Asn Ser Gly 235 240 245	190
ATT CGT CCT GCG ATT GAT GCT GGT TCT TCA GTA TCA CGT GTT GGT GGT Ile Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly 250 255 260	238
TCA GCA CAA ATC AAA GCA ATG AAG AAA GTT GCT GGT ACC CTT CGT CTT Ser Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu 265 270 275	286
GAC TTG GCT TCT CAC CGT GAA CTT GAA GCC TTT ACA CAA TTC GGT TCT Asp Leu Ala Ser His Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser 280 285 290 295	334
GAT TTG GAT GCC GCA ACA CAA GCT AAA CTT AAT CGT GGA CGT CGT ACA Asp Leu Asp Ala Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr 300 305 310	382
GTT GAA GTG CTT AAA CAA CCA CTT CAT AAC CCA CTT CCG GTT GAA AAA Val Glu Val Leu Lys Gln Pro Leu His Asn Pro Leu Pro Val Glu Lys 315 320 325	430
CAA GTT CTT ATT CTT TAC GCT TTG ACA CAT GGC TTC TTG GAC AGT GTT Gln Val Leu Ile Leu Tyr Ala Leu Thr His Gly Phe Leu Asp Ser Val 330 335 340	478
CCG GTT GAT CAA ATC TTG GAT TTT GAA GAA GCC CTC TAT GAC TAC TTT Pro Val Asp Gln Ile Leu Asp Phe Glu Glu Ala Leu Tyr Asp Tyr Phe 345 350 355	526
GAT AGC CAT CAT GAG GAT ATC TTT GAA ACA ATC CGT TCA ACT AAG GAT Asp Ser His His Glu Asp Ile Phe Glu Thr Ile Arg Ser Thr Lys Asp 360 365 370 375	574
CTT CCT GAA GAA GCT GTG CTT AAT GAA GCT ATC CAA GCT TTC AAA GAT Leu Pro Glu Glu Ala Val Leu Asn Glu Ala Ile Gln Ala Phe Lys Asp 380 385 390	622
CAA TCG GAA TAC AAA TAGAGATAGG GAGGACAGCA T ATG GCA GGC TCT CTA Gln Ser Glu Tyr Lys Met Ala Gly Ser Leu 395 1 5	673
AGA GAA ATC AAA GCA AAA ATT GCT TCA ATT AAG CAA ACG AGT CAT ATT Arg Glu Ile Lys Ala Lys Ile Ala Ser Ile Lys Gln Thr Ser His Ile 10 15 20	721
ACA GGA GCC ATG CAA ATG GTT TCT GCT TCT AAA TTG ACA CGT TCT GAG Thr Gly Ala Met Gln Met Val Ser Ala Ser Lys Leu Thr Arg Ser Glu 25 30 35	769
CAG GCT GCT AAA GAT TTC CAA ATC TAT GCC TCA AAA ATT AGA CAG ATC Gln Ala Ala Lys Asp Phe Gln Ile Tyr Ala Ser Lys Ile Arg Gln Ile 40 45 50	817
ACA ACA GAT CTT CTA CAT TCA GAA TTG GTT AAT GGT TCT TCA AAT CCG Thr Thr Asp Leu Leu His Ser Glu Leu Val Asn Gly Ser Ser Asn Pro 55 60 65	865
ATG TTG GAT GCA CGT CCA GTT CGT AAG TCA GGG TAT ATT GTC ATT ACT Met Leu Asp Ala Arg Pro Val Arg Lys Ser Gly Tyr Ile Val Ile Thr 70 75 80 85	913

TCA	GAT	AAG	GGA	TTA	GTT	GGA	GGA	TAT	AAT	TCA	ACC	ATT	CTT	AAA	GCT	961
Ser	Asp	Lys	Gly	Leu	Val	Gly	Gly	Tyr	Asn	Ser	Thr	Ile	Leu	Lys	Ala	
				90					95					100		
GTC	TTG	GAT	ATG	ATT	AAA	CGT	GAC	CAT	GAT	TCT	GAA	GAT	GAA	TAT	GCT	1009
Val	Leu	Asp	Met	Ile	Lys	Arg	Asp	His	Asp	Ser	Glu	Asp	Glu	Tyr	Ala	
			105					110					115			
ATC	ATC	TCT	ATT	GGT	GGA	ACA	GGT	TCA	GAT	TTC	TTC	AAA	GCT	CGT	AAC	1057
Ile	Ile	Ser	Ile	Gly	Gly	Thr	Gly	Ser	Asp	Phe	Phe	Lys	Ala	Arg	Asn	
		120					125					130				
ATG	AAT	GTT	GCT	TTT	GAA	CTT	CGT	GGC	CTT	GAA	GAT	CAA	CCT	AGT	TTC	1105
Met	Asn	Val	Ala	Phe	Glu	Leu	Arg	Gly	Leu	Glu	Asp	Gln	Pro	Ser	Phe	
	135					140					145					
GAT	CAA	GTC	GGG	GAA	ATC	ATT	CTA	AAA	GCT	GTA	GGA	ATG	TAT	CAA	AAT	1153
Asp	Gln	Val	Gly	Glu	Ile	Ile	Leu	Lys	Ala	Val	Gly	Met	Tyr	Gln	Asn	
150					155					160					165	
GAG	CTT	TTT	GAT	GAA	CTT	TAT	GTG	TGT	TAC	AAT	CAT	CAT	ATT	AAT	AGT	1201
Glu	Leu	Phe	Asp	Glu	Leu	Tyr	Val	Cys	Tyr	Asn	His	His	Ile	Asn	Ser	
			170						175					180		
TTG	TTT	TGT	GAA	GTT	TGT	GTT	GAA	AAA	ATG	CTT	CCA	ATT	GCT	GAT	TTT	1249
Leu	Phe	Cys	Glu	Val	Cys	Val	Glu	Lys	Met	Leu	Pro	Ile	Ala	Asp	Phe	
			185					190					195			
GAT	CCT	AAT	GAA	TTT	GAA	GGC	CAT	GTA	TTG	ACC	AAG	TTT	GAA	TTG	GAA	1297
Asp	Pro	Asn	Glu	Phe	Glu	Gly	His	Val	Leu	Thr	Lys	Phe	Glu	Leu	Glu	
		200					205					210				
CCA	AGT	TGT	GAT	ACT	ATT	TTG	GAT	CAA	CTT	TTG	CCC	ACA	ATA	GTC	GGT	1345
Pro	Ser	Cys	Asp	Thr	Ile	Leu	Asp	Gln	Leu	Leu	Pro	Thr	Ile	Val	Gly	
		215				220					225					
GAG	AGT	TTT	ATC	TAC	GGT	GCT	ATC	GTA	GAT	GCC	AAA	ACA	GCT	GAG	CAT	1393
Glu	Ser	Phe	Ile	Tyr	Gly	Ala	Ile	Val	Asp	Ala	Lys	Thr	Ala	Glu	His	
230					235					240					245	
GCT	GCT	GGT	ATG	ACC	GCA	ATG	CAG	ACT	GCC	ACT	GAT	AAT	GCT	AAG	AAA	1441
Ala	Ala	Gly	Met	Thr	Ala	Met	Gln	Thr	Ala	Thr	Asp	Asn	Ala	Lys	Lys	
				250					255					260		
ATA	ATT	AAC	GAT	TTA	ACA	ATT	CAA	TAC	AAC	CGT	GCA	CGT	CAA	GCA	GCC	1489
Ile	Ile	Asn	Asp	Leu	Thr	Ile	Gln	Tyr	Asn	Arg	Ala	Arg	Gln	Ala	Ala	
			265					270					275			
ATT	ACT	CAG	GAA	ATC	ACT	GAG	ATT	GTT	GGC	GGT	GCT	AGT	GCA	CTT	GAA	1537
Ile	Thr	Gln	Glu	Ile	Thr	Glu	Ile	Val	Gly	Gly	Ala	Ser	Ala	Leu	Glu	
		280					285					290				
TAGCTAGAGA TTTGTCTTGA TTTGACATAC AATAAAAAGG GATGATTGTC ATCCAGAAAA																1597
CTTCATAAGG AGAAAAACA ATG AGC TCA GGC AAA ATT GCT CAG GTT GTT GGT																1648
					Met	Ser	Ser	Gly	Lys	Ile	Ala	Gln	Val	Val	Gly	
					1				5					10		
CCT	GTT	GTA	GAC	GTA	GCG	TTT	GCA	ACT	GGC	GAT	AAA	CTT	CCT	GAG	ATT	1696
Pro	Val	Val	Asp	Val	Ala	Phe	Ala	Thr	Gly	Asp	Lys	Leu	Pro	Glu	Ile	
			15					20					25			

AAC AAT GCA TTG GTC GTT TAC ACT GAG AAG AAA AGT CTT AGA CGG ATG	1744
Asn Asn Ala Leu Val Val Tyr Thr Glu Lys Lys Ser Leu Arg Arg Met	
30 35 40	
GTG CTC GAA GTA GCT TCG TTG AAA CTT GGA GAA GGT GTG GTT CGT ACC	1792
Val Leu Glu Val Ala Ser Leu Lys Leu Gly Glu Gly Val Val Arg Thr	
45 50 55	
ATT GCC ATG GAA TCT ACT GAT GGA TTG ACT CGT GGG CTA GAA GTT CTG	1840
Ile Ala Met Glu Ser Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu	
60 65 70 75	
GAC ACA GGT CGT CCA ATC AGT GTT CCT GTT GGT AAA GAA CTT CTT GGA	1888
Asp Thr Gly Arg Pro Ile Ser Val Pro Val Gly Lys Glu Leu Leu Gly	
80 85 90	
CGT GTC TTT AAC GTG CTT GGA GAT ACC ATT GAC ATG GAA GCA CCT TTT	1936
Arg Val Phe Asn Val Leu Gly Asp Thr Ile Asp Met Glu Ala Pro Phe	
95 100 105	
GCA GAT GAT GCA GAG CGT GAA CCA ATT CAT AAA AAA GCA CCT ACC TTC	1984
Ala Asp Asp Ala Glu Arg Glu Pro Ile His Lys Lys Ala Pro Thr Phe	
110 115 120	
GAT GAA TTG TCA ACA AGT ACT GAA ATC CTT GAA ACA GGG ATT AAA GTT	2032
Asp Glu Leu Ser Thr Ser Thr Glu Ile Leu Glu Thr Gly Ile Lys Val	
125 130 135	
ATC GAC TTG CTT GCC CCT TAT CTT AAA GGT GGT AAA GTC GGA CTT TTC	2080
Ile Asp Leu Leu Ala Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe	
140 145 150 155	
GGT GGT GCC GGT GTT GGT AAG GCC GTT CTT ATT CAA GAG CTG AAT CAC	2128
Gly Gly Ala Gly Val Gly Lys Ala Val Leu Ile Gln Glu Leu Asn His	
160 165 170	
AAC ATT GCT CAA GAA CAC GGT GGC ATT TCC GTG	2161
Asn Ile Ala Gln Glu His Gly Gly Ile Ser Val	
175 180	

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Asp Ser His Leu His Ser Arg Leu Leu Glu Arg Ser Ala Lys Leu Ser	
1 5 10 15	
Asp Asp Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Ile Ile Gln Thr	
20 25 30	
Gln Ala Gly Asp Ile Ser Ala Tyr Ile Ala Thr Asn Val Ile Ser Ile	
35 40 45	
Thr Asp Gly Gln Ile Phe Leu Gln Glu Asn Leu Phe Asn Ser Gly Ile	
50 55 60	

```

Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly Ser
65              70              75              80
Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu Asp
85              90              95
Leu Ala Ser His Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser Asp
100            105            110
Leu Asp Ala Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr Val
115            120            125
Glu Val Leu Lys Gln Pro Leu His Asn Pro Leu Pro Val Glu Lys Gln
130            135            140
Val Leu Ile Leu Tyr Ala Leu Thr His Gly Phe Leu Asp Ser Val Pro
145            150            155            160
Val Asp Gln Ile Leu Asp Phe Glu Glu Ala Leu Tyr Asp Tyr Phe Asp
165            170            175
Ser His His Glu Asp Ile Phe Glu Thr Ile Arg Ser Thr Lys Asp Leu
180            185            190
Pro Glu Glu Ala Val Leu Asn Glu Ala Ile Gln Ala Phe Lys Asp Gln
195            200            205
Ser Glu Tyr Lys
210

```

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 293 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

```

Met Ala Gly Ser Leu Arg Glu Ile Lys Ala Lys Ile Ala Ser Ile Lys
1              5              10              15
Gln Thr Ser His Ile Thr Gly Ala Met Gln Met Val Ser Ala Ser Lys
20            25            30
Leu Thr Arg Ser Glu Gln Ala Ala Lys Asp Phe Gln Ile Tyr Ala Ser
35            40            45
Lys Ile Arg Gln Ile Thr Thr Asp Leu Leu His Ser Glu Leu Val Asn
50            55            60
Gly Ser Ser Asn Pro Met Leu Asp Ala Arg Pro Val Arg Lys Ser Gly
65              70              75              80
Tyr Ile Val Ile Thr Ser Asp Lys Gly Leu Val Gly Gly Tyr Asn Ser
85              90              95
Thr Ile Leu Lys Ala Val Leu Asp Met Ile Lys Arg Asp His Asp Ser
100            105            110

```

Glu Asp Glu Tyr Ala Ile Ile Ser Ile Gly Gly Thr Gly Ser Asp Phe
 115 120 125
 Phe Lys Ala Arg Asn Met Asn Val Ala Phe Glu Leu Arg Gly Leu Glu
 130 135 140
 Asp Gln Pro Ser Phe Asp Gln Val Gly Glu Ile Ile Leu Lys Ala Val
 145 150 155 160
 Gly Met Tyr Gln Asn Glu Leu Phe Asp Glu Leu Tyr Val Cys Tyr Asn
 165 170 175
 His His Ile Asn Ser Leu Phe Cys Glu Val Cys Val Glu Lys Met Leu
 180 185 190
 Pro Ile Ala Asp Phe Asp Pro Asn Glu Phe Glu Gly His Val Leu Thr
 195 200 205
 Lys Phe Glu Leu Glu Pro Ser Cys Asp Thr Ile Leu Asp Gln Leu Leu
 210 215 220
 Pro Thr Ile Val Gly Glu Ser Phe Ile Tyr Gly Ala Ile Val Asp Ala
 225 230 235 240
 Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala Met Gln Thr Ala Thr
 245 250 255
 Asp Asn Ala Lys Lys Ile Ile Asn Asp Leu Thr Ile Gln Tyr Asn Arg
 260 265 270
 Ala Arg Gln Ala Ala Ile Thr Gln Glu Ile Thr Glu Ile Val Gly Gly
 275 280 285
 Ala Ser Ala Leu Glu
 290

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 182 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Met Ser Ser Gly Lys Ile Ala Gln Val Val Gly Pro Val Val Asp Val
 1 5 10 15
 Ala Phe Ala Thr Gly Asp Lys Leu Pro Glu Ile Asn Asn Ala Leu Val
 20 25 30
 Val Tyr Thr Glu Lys Lys Ser Leu Arg Arg Met Val Leu Glu Val Ala
 35 40 45
 Ser Leu Lys Leu Gly Glu Gly Val Val Arg Thr Ile Ala Met Glu Ser
 50 55 60
 Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Arg Pro
 65 70 75 80

[illegible]

(2) INFORMATION FOR SEO ID NO: 14:

- ```

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 914 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: C-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Phaffia rhodozyma

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 51..824
 (D) OTHER INFORMATION: /partial
 /codon_start= 51
 /product= "ATPase subunit, partial sequence"
 /gene= "ATP2"
 /standard_name= "beta subunit of the F1 portion of
 the F0F1 ATPase"
 /label= beta-subunit

```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

|                                                                                |         |
|--------------------------------------------------------------------------------|---------|
| GAATTCTCAA CCTTGAGGGT GACTCCAAGG TCGCTCTGT CTTCGGACAG ATG AAC                  | 56      |
|                                                                                | Met Asn |
| <br>                                                                           |         |
| GAG CCC CCG GGT GCT CGA GCC CGA GTC GCT TTG ACT GGT TTG ACC ATC                | 104     |
| Glu Pro Pro Gly Ala Arg Ala Arg Val Ala Leu Thr Gly Leu Thr Ile                |         |
| 185                      190                      195                      200 |         |

|                                                                                                                                                       |     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| GCC GAG TAC TTC CGA GAC GAG GAA GGA CAG GAT GTC TTG CTT TTC ATC<br>Ala Glu Tyr Phe Arg Asp Glu Glu Gly Gln Asp Val Leu Leu Phe Ile<br>205 210 215     | 152 |
| GAC AAC ATT TTC CGA TTC ACC CAG GCC GGT TCT GAG GTG TCT GCC TTG<br>Asp Asn Ile Phe Arg Phe Thr Gln Ala Gly Ser Glu Val Ser Ala Leu<br>220 225 230     | 200 |
| CTT GGT CGA ATT CCC TCC GCC GTC GGA TAC CAG CCC ACT CTT TCC ACC<br>Leu Gly Arg Ile Pro Ser Ala Val Gly Tyr Gln Pro Thr Leu Ser Thr<br>235 240 245     | 248 |
| GAT ATG GGA GGT ATG CAG GAG CGA ATT ACC ACC ACC AAG AAG GGA TCC<br>Asp Met Gly Gly Met Gln Glu Arg Ile Thr Thr Thr Lys Lys Gly Ser<br>250 255 260     | 296 |
| ATC ACT TCC GTC CAG GCC GTC TAC GTG CCT GCT GAT GAT TTG ACC GAT<br>Ile Thr Ser Val Gln Ala Val Tyr Val Pro Ala Asp Asp Leu Thr Asp<br>265 270 275 280 | 344 |
| CCT GCC CCC GCC ACC ACC TTC GCC CAC TTG GAC GCC ACC ACT GTG TTG<br>Pro Ala Pro Ala Thr Thr Phe Ala His Leu Asp Ala Thr Thr Val Leu<br>285 290 295     | 392 |
| TCT CGA GGT ATC GCT GAG TTG GGT ATC TAC CCC GCT GTC GAT CCC CTT<br>Ser Arg Gly Ile Ala Glu Leu Gly Ile Tyr Pro Ala Val Asp Pro Leu<br>300 305 310     | 440 |
| GAT TCT AAG TCC CGA ATG CTC GAC CCC CGA ATT GTC GGA CAG GAG CAC<br>Asp Ser Lys Ser Arg Met Leu Asp Pro Arg Ile Val Gly Gln Glu His<br>315 320 325     | 488 |
| TAC GAC ATC GCC ACC AAG ACC CAG AAG ATC CTC CAG GAC TAC AAG TCC<br>Tyr Asp Ile Ala Thr Lys Thr Gln Lys Ile Leu Gln Asp Tyr Lys Ser<br>330 335 340     | 536 |
| CTC CAG GAT ATC ATT GCC ATT CTT GGT ATG GAT GAG TTG TCT GAG GAG<br>Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser Glu Glu<br>345 350 355 360 | 584 |
| GAC AAG TTG ACC GTC GAG CGA GCC CGA AAG ATC CAG CGA TTC ATG TCG<br>Asp Lys Leu Thr Val Glu Arg Ala Arg Lys Ile Gln Arg Phe Met Ser<br>365 370 375     | 632 |
| CAG CCT TTC GCT GTC GCT CAG GTC TTC ACT GGT ATC GAG GGA AAG CTT<br>Gln Pro Phe Ala Val Ala Gln Val Phe Thr Gly Ile Glu Gly Lys Leu<br>380 385 390     | 680 |
| GTT CCC TTG AAG ACT ACT TTG GAG TCC TTT AAG GAG CTT CTT TCC GGA<br>Val Pro Leu Lys Thr Thr Leu Glu Ser Phe Lys Glu Leu Leu Ser Gly<br>395 400 405     | 728 |
| GCC TGC GAC CAC CTC CCT GAG TCT GCT TTC TAC ATG GTT GGT GAC ATC<br>Ala Cys Asp His Leu Pro Glu Ser Ala Phe Tyr Met Val Gly Asp Ile<br>410 415 420     | 776 |
| GCT GAT GTC AAG GCC AAG GCT GCT GCC CAG GCT AAG GAG TTG GCT GCT<br>Ala Asp Val Lys Ala Lys Ala Ala Ala Gln Ala Lys Glu Leu Ala Ala<br>425 430 435 440 | 824 |
| TAAGAGAAGA GTTGTGCAAT GTGTTTCGAG GTGTCAGAGT TGTCTTTTAT GAATGTTTCT                                                                                     | 884 |
| ATCTCCTTAA AAAAAAAAAA AAAAAAAAAA                                                                                                                      | 914 |



## (2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 258 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

```

Met Asn Glu Pro Pro Gly Ala Arg Ala Arg Val Ala Leu Thr Gly Leu
 1 5 10 15
Thr Ile Ala Glu Tyr Phe Arg Asp Glu Glu Gly Gln Asp Val Leu Leu
 20 25 30
Phe Ile Asp Asn Ile Phe Arg Phe Thr Gln Ala Gly Ser Glu Val Ser
 35 40 45
Ala Leu Leu Gly Arg Ile Pro Ser Ala Val Gly Tyr Gln Pro Thr Leu
 50 55 60
Ser Thr Asp Met Gly Gly Met Gln Glu Arg Ile Thr Thr Thr Lys Lys
 65 70 75 80
Gly Ser Ile Thr Ser Val Gln Ala Val Tyr Val Pro Ala Asp Asp Leu
 85 90 95
Thr Asp Pro Ala Pro Ala Thr Thr Phe Ala His Leu Asp Ala Thr Thr
 100 105 110
Val Leu Ser Arg Gly Ile Ala Glu Leu Gly Ile Tyr Pro Ala Val Asp
 115 120 125
Pro Leu Asp Ser Lys Ser Arg Met Leu Asp Pro Arg Ile Val Gly Gln
 130 135 140
Glu His Tyr Asp Ile Ala Thr Lys Thr Gln Lys Ile Leu Gln Asp Tyr
 145 150 155 160
Lys Ser Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser
 165 170 175
Glu Glu Asp Lys Leu Thr Val Glu Arg Ala Arg Lys Ile Gln Arg Phe
 180 185 190
Met Ser Gln Pro Phe Ala Val Ala Gln Val Phe Thr Gly Ile Glu Gly
 195 200 205
Lys Leu Val Pro Leu Lys Thr Thr Leu Glu Ser Phe Lys Glu Leu Leu
 210 215 220
Ser Gly Ala Cys Asp His Leu Pro Glu Ser Ala Phe Tyr Met Val Gly
 225 230 235 240
Asp Ile Ala Asp Val Lys Ala Lys Ala Ala Ala Gln Ala Lys Glu Leu
 245 250 255

Ala Ala

```

## (2) INFORMATION FOR SEQ ID NO: 16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 375 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Trichoderma reesei*

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 50..361
- (D) OTHER INFORMATION: /partial  
     /codon\_start= 50  
     /product= "ATPase subunit, partial sequence"  
     /gene= "ATP2"  
     /standard\_name= "beta subunit of F1 portion of the F0F1 ATPase"  
     /label= beta-subunit

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| TACTCGAAGA ATTCGGCACG AGGCTGATTG CTCTCGGTCA TCTGCCAAG ATG TTC   | 55  |
| Met Phe                                                         |     |
| 260                                                             |     |
| AAG AGC GGC GTT TCG TCC CTC GCC AGG GCT GCC CGC CCA TCA ATT ACC | 103 |
| Lys Ser Gly Val Ser Ser Leu Ala Arg Ala Ala Arg Pro Ser Ile Thr |     |
| 265 270 275                                                     |     |
| GCT CGA CGA GCT ATC CGA CCA GCC TTC CCT CGA ACC CCC CTC GCG AGG | 151 |
| Ala Arg Arg Ala Ile Arg Pro Ala Phe Pro Arg Thr Pro Leu Ala Arg |     |
| 280 285 290                                                     |     |
| CTT GCC AGC ACC CAG AGC GTC GGA GAT GGC AAG ATC CAC CAG GTC ATT | 199 |
| Leu Ala Ser Thr Gln Ser Val Gly Asp Gly Lys Ile His Gln Val Ile |     |
| 295 300 305                                                     |     |
| GGT GCC GTC GTC GAC GTC AAG TTC GAC ACC GCC AAG CTG CCT CCT ATC | 247 |
| Gly Ala Val Val Asp Val Lys Phe Asp Thr Ala Lys Leu Pro Pro Ile |     |
| 310 315 320                                                     |     |
| CTG AAC GCC CTG GAG ACC ACC AAC AAC AAC CAG AAG CTG GTC CTC GAG | 295 |
| Leu Asn Ala Leu Glu Thr Thr Asn Asn Asn Gln Lys Leu Val Leu Glu |     |
| 325 330 335 340                                                 |     |
| GTG GCT CAA CAC TTG GGC GAG AAT GTC GTT CGC TGC ATT GCC ATG GAC | 343 |
| Val Ala Gln His Leu Gly Glu Asn Val Val Arg Cys Ile Ala Met Asp |     |
| 345 350 355                                                     |     |
| GGA TCC GAG GGT CTC GTC GTGGTTCCAA GGCA                         | 375 |
| Gly Ser Glu Gly Leu Val                                         |     |
| 360                                                             |     |

## (2) INFORMATION FOR SEQ ID NO: 17:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Phe | Lys | Ser | Gly | Val | Ser | Ser | Leu | Ala | Arg | Ala | Ala | Arg | Pro | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ile | Thr | Ala | Arg | Arg | Ala | Ile | Arg | Pro | Ala | Phe | Pro | Arg | Thr | Pro | Leu |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Ala | Arg | Leu | Ala | Ser | Thr | Gln | Ser | Val | Gly | Asp | Gly | Lys | Ile | His | Gln |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Val | Ile | Gly | Ala | Val | Val | Asp | Val | Lys | Phe | Asp | Thr | Ala | Lys | Leu | Pro |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Pro | Ile | Leu | Asn | Ala | Leu | Glu | Thr | Thr | Asn | Asn | Asn | Gln | Lys | Leu | Val |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Leu | Glu | Val | Ala | Gln | His | Leu | Gly | Glu | Asn | Val | Val | Arg | Cys | Ile | Ala |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |
| Met | Asp | Gly | Ser | Glu | Gly | Leu | Val |     |     |     |     |     |     |     |     |
|     |     |     |     | 100 |     |     |     |     |     |     |     |     |     |     |     |

## PATENT CLAIMS

1. A method of improving the production of biomass or a desired product from a cell, characterized by expressing an uncoupled ATPase activity in said cell to induce conversion of ATP to ADP without primary effects on other cellular metabolites or functions, and incubating the cell with a suitable substrate to produce said biomass or product.
2. A method according to claim 1, characterized by expressing in said cell the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity.
3. A method according to claim 1 or 2, wherein said cell is a prokaryotic cell.
4. A method according to claim 3, wherein said cell is selected from the group consisting of bacteria belonging to the genera *Lactococcus*, *Streptococcus*, *Enterococcus*, *Lactobacillus*, *Leuconostoc*, *Escherichia*, *Zymomonas*, *Bacillus* and *Pseudomonas*.
5. A method according to claim 1 or 2, wherein said cell is a eukaryotic cell.
6. A method according to claim 5, wherein said cell is a yeast cell.
7. A method according to claim 6, wherein said cell belongs to *Saccharomyces cerevisiae* or *Trichoderma reesei*.
8. A method according to any one of claims 1-7, wherein said cell is transformed or transfected with an expression vector including DNA encoding F<sub>1</sub> or a portion thereof exhibiting ATPase activity under the control of a

promoter functioning in said cell, and said DNA is expressed in the cell.

9. A method according to claim 8, wherein said DNA encoding F<sub>1</sub> or a portion thereof is homologous to said cell.

10. A method according to claim 8, wherein said DNA encoding F<sub>1</sub> or a portion thereof is heterologous to said cell.

11. A method according to any one of claims 8-10, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from a prokaryotic organism.

12. A method according to claim 11, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Escherichia coli*, *Lactococcus lactis* or *Streptococcus thermophilus* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the F<sub>1</sub> subunits  $\delta$ ,  $\alpha$ ,  $\gamma$  and  $\epsilon$  or portions thereof.

13. A method according to claim 12, wherein said DNA encoding F<sub>1</sub> or a portion thereof is selected from the group consisting of the *Escherichia coli*, *Streptococcus thermophilus* and *Lactococcus lactis* genes *atpHAGDC* (coding for subunits  $\delta$ ,  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGDC* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGD* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), *atpDC* (coding for subunits  $\beta$ ,  $\epsilon$ ) and *atpD* (coding for subunit  $\beta$  alone).

14. A method according to any one of claims 8-10, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from a eukaryotic organism.

15. A method according to claim 14, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the other F<sub>1</sub> subunits or portions thereof.

16. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Lactococcus lactis* subsp. *cremoris* and having the sequence stated in SEQ ID No. 1.

17. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Lactococcus lactis* subsp. *lactis* and having the sequence stated in SEQ ID No. 6.

18. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Streptococcus thermophilus* and having the sequence stated in SEQ ID No. 10.

19. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Phaffia rhodozyma* and having the sequence stated in SEQ ID No. 14.

20. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Trichoderma reesei* and having the sequence stated in SEQ ID No. 16.

21. An expression vector including DNA as defined in any one of claims 16-20 under the control of a promoter capable of directing the expression of said DNA in a prokaryotic or eukaryotic cell.

5

22. A method of optimizing the formation of biomass or a desired product by a cell, characterized by expressing different levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate is optimized.

15 23. A method according to claim 22, wherein a number of specimens of said cell are transformed or transfected with their respective expression vector each including DNA encoding a different portion of the cytoplasmic part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase up to and including the entire  $F_1$ , each portion exhibiting ATPase activity, said DNA in each expression vector being under the control of a promoter functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimized conversion rate.

24. A method according to claim 22, wherein a number of specimens of said cell are transformed or transfected with their respective expression vector including DNA encoding a portion of the cytoplasmic part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase up to and including the entire  $F_1$ , said portion exhibiting ATPase activity, said DNA in the respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell, incubating each cell specimen on a suitable sub-

strate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimized conversion rate.

5

25. A method according to claim 24, wherein the respective expression vectors include DNA encoding different such portions of F<sub>1</sub> up to and including the entire F<sub>1</sub>, each DNA in respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell.

10

26. A method according to any one of claims 23-25, wherein the promoter in each expression vector is an inducible promoter, and each cell specimen is grown at different concentrations of inducer.

15

27. A method according to any one of claims 23-26, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is homologous to said cell.

20

28. A method according to any one of claims 23-26, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is heterologous to said cell.

25

29. A method according to any one of claims 23-28, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from a prokaryotic organism.

30

30. A method according to claim 29, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from *Escherichia coli*, *Lactococcus lactis* or *Streptococcus thermophilus* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or

35



portion with the genes encoding the F<sub>1</sub> subunits  $\delta$ ,  $\alpha$ ,  $\gamma$  and  $\epsilon$  or portions thereof.

31. A method according to claim 30, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is selected from the group consisting of the *E. coli* genes *atpAGDC* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGD* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), *atpDC* (coding for subunits  $\beta$ ,  $\epsilon$ ) and *atpD* (coding for subunit  $\beta$  alone).

10

32. A method according to any one of claims 23-28, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from a eukaryotic organism.

15

33. A method according to claim 32, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the other F<sub>1</sub> subunits or portions thereof.

20

Fig.1





Fig. 2



3/4

Fig. 3





Fig. 4



1  
INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 97/00373

**A. CLASSIFICATION OF SUBJECT MATTER**

**IPC6: C12P 1/00, C12N 15/67**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC6: C12N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**SE,DK,FI,NO classes as above**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**WPI, CA, MEDLINE, BIOSIS**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                         | Relevant to claim No. |
|-----------|----------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | WO 8703006 A1 (GENETICS INSTITUTE, INC.), 21 May 1987 (21.05.87), see page 7, line 3-11, page 25, line 5 - page 27, line 7 | 1,3-10,22             |
| A         | --                                                                                                                         | 2,11-21, 23-33        |
| A         | EP 0645094 A1 (GIST-BROCADES N.V.), 29 March 1995 (29.03.95)                                                               | 1-33                  |
| A         | EP 0472286 A1 (MERCK & CO. INC.), 26 February 1992 (26.02.92), see claims                                                  | 16-21                 |
|           | --                                                                                                                         |                       |

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

**4 December 1997**

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Date of mailing of the international search report

**11-12-1997**

Authorized officer

**Yvonne Siösteen**  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00373

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages     | Relevant to claim No. |
|-----------|----------------------------------------------------------------------------------------|-----------------------|
| A         | WO 9400493 A1 (KAPoor, ARCHANA), 6 January 1994<br>(06.01.94), see claims<br><br>----- | 16-21                 |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

01/10/97

International application No.  
PCT/DK 97/00373

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 8703006 A1                             | 21/05/87            | AU 613307 B                | 01/08/91            |
|                                           |                     | AU 6724687 A               | 02/06/87            |
|                                           |                     | BR 8606980 A               | 03/11/87            |
|                                           |                     | CA 1312567 A               | 12/01/93            |
|                                           |                     | DE 3688743 A,T             | 26/08/93            |
|                                           |                     | DK 350287 D                | 00/00/00            |
|                                           |                     | EP 0245481 A,B             | 19/11/87            |
|                                           |                     | SE 0245481 T3              |                     |
|                                           |                     | JP 63501616 T              | 23/06/88            |
|                                           |                     | OA 8631 A                  | 30/11/88            |
|                                           |                     | US 5268285 A               | 07/12/93            |
| EP 0645094 A1                             | 29/03/95            | AU 673768 B                | 21/11/96            |
|                                           |                     | AU 7417494 A               | 06/04/95            |
|                                           |                     | CA 2132772 A               | 25/03/95            |
|                                           |                     | JP 7177877 A               | 18/07/95            |
| EP 0472286 A1                             | 26/02/92            | CA 2047028 A               | 19/01/92            |
|                                           |                     | JP 5068567 A               | 23/03/93            |
| WO 9400493 A1                             | 06/01/94            | AU 4651193 A               | 24/01/94            |
|                                           |                     | EP 0649435 A               | 26/04/95            |
|                                           |                     | JP 7508649 T               | 28/09/95            |
|                                           |                     | US 5330754 A               | 19/07/94            |
|                                           |                     | US 5559011 A               | 24/09/96            |

Form PCT/ISA/210 (patent family annex) (July 1992)